<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004583.pub2" GROUP_ID="STROKE" ID="226202120514172260" MERGED_FROM="" MODIFIED="2008-08-05 15:01:16 +0200" MODIFIED_BY="Hazel Fraser" NOTES="&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-08-05 13:51:58 +0100" NOTES_MODIFIED_BY="Hazel Fraser" REVIEW_NO="0001" REVMAN_SUB_VERSION="5.0.14" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.0">
<COVER_SHEET MODIFIED="2008-08-05 15:01:16 +0200" MODIFIED_BY="Hazel Fraser">
<TITLE>Corticosteroids for aneurysmal subarachnoid haemorrhage and primary intracerebral haemorrhage</TITLE>
<CONTACT MODIFIED="2008-08-05 15:01:16 +0200" MODIFIED_BY="Hazel Fraser"><PERSON ID="16466" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Valery</FIRST_NAME><MIDDLE_INITIALS>L</MIDDLE_INITIALS><LAST_NAME>Feigin</LAST_NAME><POSITION>Director, National Research Centre for Stroke, Applied Neurosciences &amp; Neurorehabilitation</POSITION><EMAIL_1>valery.feigin@aut.ac.nz</EMAIL_1><MOBILE_PHONE>+64 27 4646200</MOBILE_PHONE><ADDRESS><DEPARTMENT>Faculty of Health &amp; Environmental Sciences</DEPARTMENT><ORGANISATION>Auckland University of Technology</ORGANISATION><ADDRESS_1>Private Bag 92006</ADDRESS_1><CITY>Auckland</CITY><ZIP>1142</ZIP><COUNTRY CODE="NZ">New Zealand</COUNTRY><PHONE_1>+64 9 921 9166</PHONE_1><FAX_1>+64 9 921 9620</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-08-05 15:01:16 +0200" MODIFIED_BY="Hazel Fraser"><PERSON ID="16466" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Valery</FIRST_NAME><MIDDLE_INITIALS>L</MIDDLE_INITIALS><LAST_NAME>Feigin</LAST_NAME><POSITION>Director, National Research Centre for Stroke, Applied Neurosciences &amp; Neurorehabilitation</POSITION><EMAIL_1>valery.feigin@aut.ac.nz</EMAIL_1><MOBILE_PHONE>+64 27 4646200</MOBILE_PHONE><ADDRESS><DEPARTMENT>Faculty of Health &amp; Environmental Sciences</DEPARTMENT><ORGANISATION>Auckland University of Technology</ORGANISATION><ADDRESS_1>Private Bag 92006</ADDRESS_1><CITY>Auckland</CITY><ZIP>1142</ZIP><COUNTRY CODE="NZ">New Zealand</COUNTRY><PHONE_1>+64 9 921 9166</PHONE_1><FAX_1>+64 9 921 9620</FAX_1></ADDRESS></PERSON><PERSON ID="16429" ROLE="AUTHOR"><PREFIX>A/Prof</PREFIX><FIRST_NAME>Neil</FIRST_NAME><LAST_NAME>Anderson</LAST_NAME><POSITION>Consultant Neurologist</POSITION><ADDRESS><DEPARTMENT>Department of Medicine</DEPARTMENT><ORGANISATION>University of Auckland</ORGANISATION><ADDRESS_1>Private Bag 92019</ADDRESS_1><CITY>Auckland</CITY><ZIP>92019</ZIP><COUNTRY CODE="NZ">New Zealand</COUNTRY><PHONE_1>+64 9 373 7599 ext: 86262</PHONE_1><FAX_1>+64 9 373 7677</FAX_1></ADDRESS></PERSON><PERSON ID="5605" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Gabriel</FIRST_NAME><MIDDLE_INITIALS>JE</MIDDLE_INITIALS><LAST_NAME>Rinkel</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Professor of Neurology</POSITION><EMAIL_1>g.j.e.rinkel@umcutrecht.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>University Medical Center Utrecht</ORGANISATION><ADDRESS_1>PO Box 85500</ADDRESS_1><CITY>Utrecht</CITY><ZIP>3508 GA</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 30 2508 600</PHONE_1><FAX_1>+31 30 2542 100</FAX_1></ADDRESS></PERSON><PERSON ID="5496" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Ale</FIRST_NAME><LAST_NAME>Algra</LAST_NAME><POSITION>Clinical Epidemiologist</POSITION><EMAIL_1>a.algra@umcutrecht.nl</EMAIL_1><ADDRESS><DEPARTMENT>Julius Centre for Health Sciences and Primary Care</DEPARTMENT><ORGANISATION>University Medical Center Utrecht</ORGANISATION><ADDRESS_1>PO Box 85500</ADDRESS_1><CITY>Utrecht</CITY><ZIP>3508 GA</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 30 250 9350</PHONE_1><PHONE_2>+31 30 250 8350</PHONE_2><FAX_1>+31 30 250 5485</FAX_1></ADDRESS></PERSON><PERSON ID="5646" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Jan</FIRST_NAME><LAST_NAME>van Gijn</LAST_NAME><EMAIL_1>j.vangijn@neuro.azu.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>University Medical Center Utrecht</ORGANISATION><ADDRESS_1>PO Box 85500</ADDRESS_1><CITY>Utrecht</CITY><ZIP>3508 GA</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 30 2507975</PHONE_1><FAX_1>+31 30 2542100</FAX_1></ADDRESS></PERSON><PERSON ID="14647" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Derrick</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Bennett</LAST_NAME><POSITION>Senior Biostatistician</POSITION><EMAIL_1>derrick.bennett@ctsu.ox.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Clinical Trials Service Unit and Epidemiological Studies Unit</DEPARTMENT><ORGANISATION>Oxford University</ORGANISATION><ADDRESS_1>Richard Doll Building</ADDRESS_1><ADDRESS_2>Radcliffe Infirmary</ADDRESS_2><CITY>Oxford</CITY><ZIP>OX3 7LF</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 1865 743949</PHONE_1><FAX_1>+44 1865 743985</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-08-05 13:31:08 +0100" MODIFIED_BY="Hazel Fraser">
<UP_TO_DATE>
<DATE DAY="30" MONTH="4" YEAR="2004"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="31" MONTH="3" YEAR="2004"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2004"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2005"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2005"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="5" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-08-05 13:31:23 +0100" MODIFIED_BY="Hazel Fraser"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>University of Auckland</NAME>
<COUNTRY CODE="NZ">New Zealand</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>University Hospital of Utrecht</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-08-05 13:51:58 +0100" MODIFIED_BY="Hazel Fraser">
<SUMMARY MODIFIED="2008-08-05 13:34:24 +0100" MODIFIED_BY="Hazel Fraser">
<TITLE MODIFIED="2008-08-05 13:34:24 +0100" MODIFIED_BY="Hazel Fraser">Corticosteroids for aneurysmal subarachnoid haemorrhage and primary intracerebral haemorrhage</TITLE>
<SUMMARY_BODY MODIFIED="2008-08-05 13:34:12 +0100" MODIFIED_BY="Hazel Fraser">
<P>There is no evidence of benefit from corticosteroids for patients with stroke due to bleeding. About one fifth of all strokes are due to bursting of an artery. The burst artery causes bleeding into the brain itself (called intracerebral haemorrhage) or into the space around the brain (called subarachnoid haemorrhage). After either type of bleed the brain tissue may become swollen. The swelling causes a rise in pressure which can cause further brain damage or even death. Corticosteroids could reduce swelling after brain haemorrhage and so improve the chances of the patient recovering. However, corticosteroids can also have important adverse effects such as increased blood sugars, infection, and gastrointestinal bleeding. The trials included in this review had too few participants to provide reliable evidence on any benefits weighed against harms of this treatment for patients with stroke due to bleeding in the brain.<BR/>
</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-08-05 13:48:59 +0100" MODIFIED_BY="Hazel Fraser">
<ABS_BACKGROUND>
<P>Corticosteroids, particularly dexamethasone, are commonly used for treatments in patients with subarachnoid haemorrhage (SAH) and primary intracerebral haemorrhage (PICH) despite the lack of evidence.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2008-08-05 13:45:27 +0100" MODIFIED_BY="Hazel Fraser">
<P>To determine: (1) whether corticosteroid therapy reduces the proportion of patients who die or have a poor outcome at one to six months after the onset of SAH or PICH; (2) whether corticosteroid therapy reduces the frequency of delayed cerebral ischaemia in patients with SAH; (3) the frequency of adverse effects of corticosteroid therapy in patients with SAH or PICH within six months of the onset of the event.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-08-05 13:43:21 +0100" MODIFIED_BY="Hazel Fraser">
<P>We searched the Cochrane Stroke Group Trials Register (last searched November 2003). In addition, we searched MEDLINE (1966 to March 2004) and EMBASE (1980 to March 2004), and searched reference lists of relevant studies identified. We attempted to identify any relevant ongoing and published or unpublished studies by contacting trialists and pharmaceutical companies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2008-08-05 13:44:02 +0100" MODIFIED_BY="Hazel Fraser">
<P>We sought to identify all randomised or quasi-randomised clinical trials of corticosteroid therapy, in patients with SAH or PICH, that have a placebo or standard strategy arm as control. Data were analysed both separately and combined for computed tomography (CT)/magnetic resonance imaging (MRI)/autopsy/angiography verified patients.<BR/>
</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2008-08-05 13:45:48 +0100" MODIFIED_BY="Hazel Fraser">
<P>Data extracted from eligible clinical trials included: (1) death and poor outcome (death, severe disability, or vegetative state) within the first one to six months of the event onset (primary outcomes); (2) development of delayed cerebral ischaemia in patients with SAH; and (3) adverse effects of the treatment during the scheduled treatment or follow-up period (secondary outcomes). A pooled estimate of the effect size was computed, and the test for heterogeneity between trial results was carried out. Intention-to-treat analysis was carried out whenever possible.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-08-05 13:48:59 +0100" MODIFIED_BY="Hazel Fraser">
<P>Eight trials, with 256 randomised patients in three SAH trials and 206 patients in five PICH trials, were included. The studies differed substantially with regard to the study populations and drugs, and methodological quality. The number of patients allocated to either hydrocortisone or fludrocortisone acetate treatment in patients with SAH, or to dexamethasone treatment in patients with PICH, was too small to make any definitive conclusions.<BR/>
</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Overall, there is no evidence of a beneficial or adverse effect of corticosteroids in patients with either SAH or PICH. Confidence intervals are wide and include clinically significant effects in both directions. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-08-05 13:51:58 +0100" MODIFIED_BY="Hazel Fraser">
<BACKGROUND>
<P>Subarachnoid haemorrhage (SAH) and primary intracerebral haemorrhage (PICH) currently account for approximately 20% of all strokes and lead to early death (within one month) in about 50% of the patients (<LINK REF="REF-Feigin-2003" TYPE="REFERENCE">Feigin 2003</LINK>; <LINK REF="REF-Hop-1997" TYPE="REFERENCE">Hop 1997</LINK>). Delayed cerebral ischaemia (DCI) in patients with aneurysmal SAH (<LINK REF="REF-Ljunggren-1983" TYPE="REFERENCE">Ljunggren 1983</LINK>; <LINK REF="REF-Longstreth-1993" TYPE="REFERENCE">Longstreth 1993</LINK>) and secondary perifocal brain oedema after PICH (<LINK REF="REF-Clasen-1980" TYPE="REFERENCE">Clasen 1980</LINK>) remain major causes of death and poor functional outcome in these patients. Advanced patient age (more than 60 years), a deep location of the haemorrhage, and size of the haematoma of more than 40 ml have been related to poor outcome in patients with PICH (<LINK REF="REF-Beldman-1996" TYPE="REFERENCE">Beldman 1996</LINK>), while a large amount of subarachnoid blood on computed tomography (CT) scan (<LINK REF="REF-Brouwers-1993" TYPE="REFERENCE">Brouwers 1993</LINK>), and a depressed level of consciousness on admission (<LINK REF="REF-Hijdra-1988" TYPE="REFERENCE">Hijdra 1988</LINK>; <LINK REF="REF-Hop-1999" TYPE="REFERENCE">Hop 1999</LINK>) are important predictors for the development of DCI in patients with aneurysmal SAH. </P>
<P>Decreasing plasma volume (<LINK REF="REF-Wijdicks-1985" TYPE="REFERENCE">Wijdicks 1985</LINK>), hyponatraemia (<LINK REF="REF-Wijdicks-1985" TYPE="REFERENCE">Wijdicks 1985</LINK>; <LINK REF="REF-Wijdicks-1988a" TYPE="REFERENCE">Wijdicks 1988a</LINK>), impaired autoregulation of cerebral blood flow (<LINK REF="REF-Ischii-1979" TYPE="REFERENCE">Ischii 1979</LINK>), and reactive inflammation (<LINK REF="REF-Chyatte-1987" TYPE="REFERENCE">Chyatte 1987</LINK>) are important contributing factors to the development of DCI after aneurysmal SAH. Moreover, mineralocorticoid treatment with fludrocortisone acetate prevents plasma volume depletion (<LINK REF="REF-Wijdicks-1988b" TYPE="REFERENCE">Wijdicks 1988b</LINK>) and glucocorticoid treatment (methylprednisolone with or without cortisol) has an anti-inflammatory effect (<LINK REF="REF-Chyatte-1983" TYPE="REFERENCE">Chyatte 1983</LINK>) and results in cerebral vasodilation (<LINK REF="REF-Fox-1975" TYPE="REFERENCE">Fox 1975</LINK>; <LINK REF="REF-Hashi-1980" TYPE="REFERENCE">Hashi 1980</LINK>) and improvement of cerebral blood flow (<LINK REF="REF-Yamakawa-1991" TYPE="REFERENCE">Yamakawa 1991</LINK>) following SAH. However, a beneficial effect of steroids on clinical outcome in patients with SAH has not been proven (<LINK REF="REF-Meyer-1995" TYPE="REFERENCE">Meyer 1995</LINK>). Although corticosteroids may also have a beneficial effect in patients with PICH it has been suggested that in patients with putamino-capsular haemorrhages steroids have a harmful effect on the clinical outcome (<LINK REF="REF-De-Reuck-1989" TYPE="REFERENCE">De Reuck 1989</LINK>). Moreover, many studies found an increased frequency of complications such as gastrointestinal bleeding, infection, and exacerbation of diabetes mellitus in patients treated with corticosteroids after a haemorrhagic stroke (<LINK REF="REF-Bauer-1973" TYPE="REFERENCE">Bauer 1973</LINK>; <LINK REF="REF-Norris-1976" TYPE="REFERENCE">Norris 1976</LINK>; <LINK REF="STD-Poungvarin-1987" TYPE="STUDY">Poungvarin 1987</LINK>; <LINK REF="STD-Tellez-1973" TYPE="STUDY">Tellez 1973</LINK>). Despite the lack of evidence, corticosteroids, particularly dexamethasone, are commonly used for treatments in patients with SAH and PICH (<LINK REF="STD-Desai-1998" TYPE="STUDY">Desai 1998</LINK>; <LINK REF="REF-Karnik-1990" TYPE="REFERENCE">Karnik 1990</LINK>; <LINK REF="REF-Kase-1991" TYPE="REFERENCE">Kase 1991</LINK>; <LINK REF="REF-Longstreth-1993" TYPE="REFERENCE">Longstreth 1993</LINK>).</P>
<P>In order to assess the efficacy and safety of corticosteroids in the treatment of patients with acute SAH and PICH we performed a systematic overview of all randomised controlled trials in this field.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2008-08-05 13:35:18 +0100" MODIFIED_BY="Hazel Fraser">
<P>To determine:</P>
<UL>
<LI>whether corticosteroid therapy reduces the proportion of patients who die or have a poor outcome at one to six months after the onset of SAH or PICH;</LI>
<LI>whether corticosteroid therapy reduces the frequency of DCI in patients with SAH;</LI>
<LI>the frequency of adverse effects of corticosteroid therapy in patients with SAH and PICH within six months of the onset of the event.</LI>
</UL>
</OBJECTIVES>
<METHODS MODIFIED="2008-08-05 13:51:58 +0100" MODIFIED_BY="Hazel Fraser">
<SELECTION_CRITERIA MODIFIED="2008-08-05 13:35:46 +0100" MODIFIED_BY="Hazel Fraser">
<CRIT_STUDIES>
<P>We sought to identify all randomised and quasi-randomised clinical trials of corticosteroid therapy in patients with SAH or PICH that have a placebo or standard strategy arm as the control. Uncontrolled studies were excluded from the analysis. Controlled trials where allocation to treatment or control group was not adequately concealed (for example, allocation by alternation, open random number list, date of birth, day of the week , or hospital number) were included in the analysis, but analysed separately as well.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Patients of any age and either gender with PICH documented by either CT/MRI scanning, brain autopsy, or angiography. Patients with clinically (bed-side) diagnosed PICH were included in the analysis but analysed both separately and combined with CT/MRI/autopsy/angiography verified patients. Patients of any age and either gender with SAH documented by CT scan, MRI, angiography, or cerebrospinal fluid examination. These patients could be of any clinical condition before the start of corticosteroid therapy.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Corticosteroid therapy of any type (mineralocorticoids, glucocorticoids) and regardless of dosage and mode of administration (intravenously, orally, or both). This treatment could be started before or after aneurysm/haematoma surgery. </P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-08-05 13:35:46 +0100" MODIFIED_BY="Hazel Fraser">
<P>The main outcomes of interest extracted from each treatment group were the following.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome measures</HEADING>
<UL>
<LI>death within the first one to six months of the event onset;</LI>
<LI>poor outcome (death, severe disability, or vegetative state) within the first one to six months of the event onset.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcome measures</HEADING>
<UL>
<LI>development of DCI (including clinical signs of ischaemic neurological deficit) during the scheduled treatment or follow-up period in patients with SAH;</LI>
<LI>adverse effects of the treatment (such as hypokalemia, hyperglycemia, any infection, gastrointestinal bleeding, exacerbation of diabetes mellitus) during the scheduled treatment or follow-up period.</LI>
</UL>
<P>Given that mineralocorticoids and glucocorticoids have different mechanisms of action (glucocorticoids have a predominant action on intermediary metabolism, whereas mineralocorticoids have a predominant action on the electrolyte balance of sodium and potassium), the effect of these two subgroups of drugs on clinical outcome in patients with SAH and PICH were considered separately and combined in order to minimise clinical heterogeneity. We included in the analysis the number of patients with DCI as given in the original report regardless whether or not a definition was given in that report or whether this definition was adequate. The duration of the follow-up period used for data extraction was restricted to six months.</P>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-08-05 13:37:26 +0100" MODIFIED_BY="Hazel Fraser">
<P>See: 'Specialized register' section in <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/STROKE/frame.html">Cochrane Stroke Group</A>
</P>
<P>Relevant trials were identified in the Cochrane Stroke Group's Trials Register, which was last searched by the Review Group Co-ordinator in November 2003. In addition, we searched MEDLINE (1966 to March 2004) and EMBASE (1980 to March 2004) (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>), and searched reference lists of relevant studies identified. We also made an attempt to identify any relevant ongoing and unpublished studies by contacting trialists. In 1995 and 1996, we also contacted 18 pharmaceutical companies asking them to provide information on any other relevant randomised controlled trials, published or unpublished. Sixteen of the 18 companies replied to our request: Bayer AG, Synthelabo Pharmacie, Sandoz BV, Astra, Bristol-Myers Squibb, Wyeth, Boehringer Ingelheim, Pfizer BV, Akzo Nobel, Centocor BV, Schering Nederland BV, Yamanouchi Europe BV, Amersham Healthcare, Parke-Davis, Zambon Nederland BV, UCB Pharma BV. None of these companies stated they were aware of unpublished trials. The reference lists of all relevant trials were also searched.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-08-05 13:51:58 +0100" MODIFIED_BY="Hazel Fraser">
<SUBSECTION>
<HEADING LEVEL="3">Data extraction and trial quality assessment</HEADING>
<P>Three of us (VLF, DAB, GJER) independently extracted details of randomisation methods, blinding of treatments and assessments, whether treatment groups were comparable with regard to major prognostic risk factors for outcomes, the number of patients who were excluded or lost to follow up, definition of outcomes, and entry and exclusion criteria. The methodological quality of each trial was assessed by three raters (VLF, DAB and GJER) independently from each other as described elsewhere (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>) . No discordance in the accuracy of data extraction of individual items across the raters was observed (concordance was assessed via discussion). The number of patients with each outcome of interest and side effect specified in the 'Types of outcome measures' section was also recorded. All data were independently extracted by the same three authors and cross-checked. If there were patients excluded or lost to follow up after randomisation, or if any of the above data were not available from the publications, further information was sought by contacting the trialists. If the data about patients excluded or lost to follow up remained unavailable a decision whether to include this particular trial in the review was made by all the authors of the review.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data analysis</HEADING>
<P>For each study a relative risk (RR) was computed as the measure of effect size. A pooled estimate of the effect size was computed using a standard inverse-variance fixed-effect weighting method (<LINK REF="REF-Hedges-1994" TYPE="REFERENCE">Hedges 1994</LINK>; <LINK REF="REF-Olkin-1995" TYPE="REFERENCE">Olkin 1995</LINK>). The test for heterogeneity between trial results was carried out with a standard chi squared test and I-squared statistic (<LINK REF="REF-Thompson-2002" TYPE="REFERENCE">Thompson 2002</LINK>) using The Cochrane Collaboration's Review Manager software, RevMan 4.2.</P>
<SUBSECTION>
<HEADING LEVEL="4">Sensitivity analysis</HEADING>
<P>To provide an intention-to-treat analysis, we aimed to extract from each trial the number of patients who were originally allocated to each treatment group. Any significantly positive trial which included patients excluded or lost to follow up (protocol analysis) was re-evaluated by a worst case scenario imputation. This analysis assumed that those patients excluded or lost to follow up in the treatment group had the worst outcome while those patients excluded or lost to follow up in the control group had the best outcome. Additional sensitivity analyses were carried out with estimations of relative risk by means of a random-effects model and with exclusion of trials with inferior methodological quality. The presence of publication bias was assessed by the funnel plot method as described in the Cochrane Reviewers' Handbook (<LINK REF="REF-Handbook-2004" TYPE="REFERENCE">Handbook 2004</LINK>).</P>
<P>Additional subgroup or sensitivity analyses were based on:<BR/>(1) the comparison of the efficacy of steroid therapy in truly randomised trials versus all trials;<BR/>(2) the exclusion of trials with standard strategy as control;<BR/>(3) the comparison of the efficacy of various dosages and routes of administration of steroids;<BR/>(4) the comparison of the efficacy of steroid treatment started within the first 24 hours and later than 24 hours of PICH/SAH onset.</P>
<P>Additional analyses were based on:<BR/>(1) the comparison of the efficacy of glucocorticoids and mineralocorticoids; and<BR/>(2) the comparison of the efficacy of treatment with steroids started before and after aneurysm/haematoma surgery.</P>
</SUBSECTION>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-08-05 13:40:19 +0100" MODIFIED_BY="Hazel Fraser">
<STUDY_DESCRIPTION MODIFIED="2008-08-05 13:39:55 +0100" MODIFIED_BY="Hazel Fraser">
<P>Eight trials that fulfilled the eligibility criteria were identified (256 randomised patients in three SAH trials and 206 patients in five PICH trials): two trials for mineralocorticoid treatment of SAH with intravenously or orally administered fludrocortisone acetate (<LINK REF="STD-Hasan-1989" TYPE="STUDY">Hasan 1989</LINK>; <LINK REF="STD-Mori-1999" TYPE="STUDY">Mori 1999</LINK>), one trial for glucocorticoid treatment of SAH with intravenously administered hydrocortisone (<LINK REF="STD-Hashi-1988" TYPE="STUDY">Hashi 1988</LINK>), and five trials assessing the effects of dexamethasone treatment in PICH (<LINK REF="STD-Desai-1998" TYPE="STUDY">Desai 1998</LINK>; <LINK REF="STD-Hooshmand-1972" TYPE="STUDY">Hooshmand 1972</LINK>; <LINK REF="STD-Ogun-2001" TYPE="STUDY">Ogun 2001</LINK>; <LINK REF="STD-Poungvarin-1987" TYPE="STUDY">Poungvarin 1987</LINK>; <LINK REF="STD-Tellez-1973" TYPE="STUDY">Tellez 1973</LINK>). It should be noted that the <LINK REF="STD-Hashi-1988" TYPE="STUDY">Hashi 1988</LINK> trial included patients who had DCI at baseline, therefore: (1) this trial might have included more severe patients than the other SAH trials in our overview; and (2) the development of DCI could not be evaluated in this trial. There are no SAH or PICH trials awaiting assessment. The corticosteroid drugs were classified as glucocorticoids (methyprednisolone, hydrocortisone, dexamethasone) and mineralocorticoids (fludrocortisone).<BR/>
<BR/>No ongoing randomised trials were identified for patients with SAH, but one ongoing randomised double-blinded placebo-controlled trial has been identified for patients with PICH (<LINK REF="STD-STICH_x002d_Pilot-2004" TYPE="STUDY">STICH-Pilot 2004</LINK>). In this trial 50 patients with acute (8 hours after onset) supratentorial PICH will be randomised to methylprednisone (30 mg/kg bolus followed by continuous intravenous infusion at 5.4 mg/kg/hour for 48 hours) or placebo. The key outcome measures are case fatality (30 days) and neurological morbidity (90 days) assessed by means of the Barthel Index, the modified Rankin score, the Glasgow Coma Scale, the Scandinavian Stroke Scale, or the NIH Stroke Scale.</P>
<SUBSECTION>
<HEADING LEVEL="3">Excluded studies</HEADING>
<P>One randomised double-blind clinical trial of high-dose methylprednisolone pulse in supratentorial intracerebral haemorrhage patients, started in mid 1990, was excluded from the analysis because the trial was stopped prematurely due to poor recruitment rate and lack of interest from the investigators in continuing the trial (<LINK REF="STD-Wijdicks" TYPE="STUDY">Wijdicks</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Size of the trials and treatment modes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">SAH trials</HEADING>
<P>The number of patients with SAH totalled 116 in the fludrocortisone acetate trials (<LINK REF="STD-Hasan-1989" TYPE="STUDY">Hasan 1989</LINK>; <LINK REF="STD-Mori-1999" TYPE="STUDY">Mori 1999</LINK>): 61 patients with study treatment on the top of the standard treatment and 55 control patients with standard treatment alone. Treatment (0.3 to 0.4 mg intravenously (IV) or orally in two to three doses for a maximum duration of 12 days) was started regardless of development of DCI. In the hydrocortisone trial (<LINK REF="STD-Hashi-1988" TYPE="STUDY">Hashi 1988</LINK>) 140 patients were enrolled: 71 patients with study treatment and 69 control patients receiving folic acid, considered as placebo. Treatment (3 g hydrocortisone IV in a 60 ml solution, administered six times at intervals of 12 hours) was initiated in patients who suffered from clinical signs of DCI due to vasospasm.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">PICH trials</HEADING>
<P>In patients with PICH, treatment with dexamethasone (4 to 12 mg IV or intramuscularly (IM) for 2 to 16 days) was compared with placebo in the four trials (<LINK REF="STD-Desai-1998" TYPE="STUDY">Desai 1998</LINK>; <LINK REF="STD-Ogun-2001" TYPE="STUDY">Ogun 2001</LINK>; <LINK REF="STD-Poungvarin-1987" TYPE="STUDY">Poungvarin 1987</LINK>; <LINK REF="STD-Tellez-1973" TYPE="STUDY">Tellez 1973</LINK>) (186 patients in total), and with no corticosteroid treatment in one trial (<LINK REF="STD-Hooshmand-1972" TYPE="STUDY">Hooshmand 1972</LINK>) (20 patients). Timing, daily dosage, and mode of dexamethasone treatment in the trials were similar.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Inclusion and exclusion criteria</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">SAH trials</HEADING>
<P>Inclusion criteria used in the fludrocortisone trials were as follows: any patient with symptoms and signs of SAH and with confirmatory evidence on the initial CT scan or in the cerebrospinal fluid (CSF) (<LINK REF="STD-Hasan-1989" TYPE="STUDY">Hasan 1989</LINK>), or patients with ruptured and clipped intracranial aneurysms within two days of the onset of SAH (<LINK REF="STD-Mori-1999" TYPE="STUDY">Mori 1999</LINK>). Diagnosis of SAH was documented by CT/MRI scanning or cerebral angiography in all 256 patients. Exclusion criteria in the trial by Hasan et al (<LINK REF="STD-Hasan-1989" TYPE="STUDY">Hasan 1989</LINK>) consisted of the following: a lapse of more than 72 hours after the onset of the SAH; age greater than 70 years; previous treatment with diuretics or corticosteroids; presence of endocrine, renal, or cardiac disease; moribund patients; or CT scan evidence of a cause for the SAH other than aneurysm. Patients with head trauma, known endocrine disturbances, renal disease, congestive heart failure, intracranial haematoma greater than 3 cm in diameter by CT scan were not included in the trial by Mori et al (<LINK REF="STD-Mori-1999" TYPE="STUDY">Mori 1999</LINK>). In the hydrocortisone trial (<LINK REF="STD-Hashi-1988" TYPE="STUDY">Hashi 1988</LINK>) patients with Hunt and Hess grades I to IV on admission and with clinical manifestations of delayed ischaemic neurological deficits following aneurysmal SAH were included (exclusion criteria were not stated). All these SAH trials included men and women.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">PICH trials</HEADING>
<P>CT scan or cerebral angiography confirmation of PICH was mandatory in three trials included in the analysis (<LINK REF="STD-Desai-1998" TYPE="STUDY">Desai 1998</LINK>; <LINK REF="STD-Hooshmand-1972" TYPE="STUDY">Hooshmand 1972</LINK>; <LINK REF="STD-Poungvarin-1987" TYPE="STUDY">Poungvarin 1987</LINK>) but it was not available in two other trials (<LINK REF="STD-Ogun-2001" TYPE="STUDY">Ogun 2001</LINK>; <LINK REF="STD-Tellez-1973" TYPE="STUDY">Tellez 1973</LINK>), where the diagnosis was largely based on clinical criteria and the results of CSF examination (exact methods of verification of the diagnosis were not reported in the trial by Ogun et al) (<LINK REF="STD-Ogun-2001" TYPE="STUDY">Ogun 2001</LINK>). Patients with haemorrhagic infarction or infratentorial PICH were excluded from the trial by Poungvarin et al (<LINK REF="STD-Poungvarin-1987" TYPE="STUDY">Poungvarin 1987</LINK>). In the trial by Ogun et al (<LINK REF="STD-Ogun-2001" TYPE="STUDY">Ogun 2001</LINK>) patients with infratentorial PICH were also excluded. Patients with infratentorial PICH constituted 27.5% of all randomised patients in the trial by Tellez et al (<LINK REF="STD-Tellez-1973" TYPE="STUDY">Tellez 1973</LINK>) and might have been included in the trial by Hooshmand et al (<LINK REF="STD-Hooshmand-1972" TYPE="STUDY">Hooshmand 1972</LINK>) in which no information on the location of PICH was given. Patients with previous stroke, recent head trauma, clinically apparent infection at entry, and contraindications to steroids were excluded from the PICH trials. All these PICH trials included men and women.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Outcome measures and follow-up duration</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">SAH trials</HEADING>
<P>The total duration of follow up for clinical outcomes was about one month in two SAH trials (<LINK REF="STD-Hasan-1989" TYPE="STUDY">Hasan 1989</LINK>; <LINK REF="STD-Hashi-1988" TYPE="STUDY">Hashi 1988</LINK>) and six months in the third trial (<LINK REF="STD-Mori-1999" TYPE="STUDY">Mori 1999</LINK>). In the fludrocortisone trials (<LINK REF="STD-Hasan-1989" TYPE="STUDY">Hasan 1989</LINK>; <LINK REF="STD-Mori-1999" TYPE="STUDY">Mori 1999</LINK>), the clinical outcome measures were the Glasgow Outcome Scale (<LINK REF="STD-Mori-1999" TYPE="STUDY">Mori 1999</LINK>) and the development of probable or definite DCI (<LINK REF="STD-Hasan-1989" TYPE="STUDY">Hasan 1989</LINK>). In the hydrocortisone trial (<LINK REF="STD-Hashi-1988" TYPE="STUDY">Hashi 1988</LINK>), changes in the level of consciousness (Japan coma scale), mental functions, speech and motor functions, and in activities of daily living were measured during the follow up.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">PICH trials</HEADING>
<P>In the PICH trials follow-up duration ranged from two weeks (<LINK REF="STD-Tellez-1973" TYPE="STUDY">Tellez 1973</LINK>), three weeks (<LINK REF="STD-Poungvarin-1987" TYPE="STUDY">Poungvarin 1987</LINK>), four to five weeks (<LINK REF="STD-Desai-1998" TYPE="STUDY">Desai 1998</LINK>) and up to six months (<LINK REF="STD-Ogun-2001" TYPE="STUDY">Ogun 2001</LINK>; <LINK REF="STD-Tellez-1973" TYPE="STUDY">Tellez 1973</LINK>). The number of deaths as an outcome were assessed at the end of follow up in all the PICH trials; three trials assessed dependency as an outcome (<LINK REF="STD-Desai-1998" TYPE="STUDY">Desai 1998</LINK>; <LINK REF="STD-Ogun-2001" TYPE="STUDY">Ogun 2001</LINK>; <LINK REF="STD-Poungvarin-1987" TYPE="STUDY">Poungvarin 1987</LINK>); and one trial (<LINK REF="STD-Tellez-1973" TYPE="STUDY">Tellez 1973</LINK>) recorded gastrointestinal bleeding complications.</P>
</SUBSECTION>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-08-05 13:40:07 +0100" MODIFIED_BY="Hazel Fraser">
<SUBSECTION>
<HEADING LEVEL="3">SAH trials</HEADING>
<P>Random number tables by means of a sealed envelope technique were used in one fludrocortisone trial (<LINK REF="STD-Hasan-1989" TYPE="STUDY">Hasan 1989</LINK>) while the exact method of randomisation was not specified in the other fludrocortisone trial (<LINK REF="STD-Mori-1999" TYPE="STUDY">Mori 1999</LINK>). In the hydrocortisone trial (<LINK REF="STD-Hashi-1988" TYPE="STUDY">Hashi 1988</LINK>) the exact method of randomisation was not specified but it was stated that the randomisation was done on the basis of a standard method by an independent physician who was not otherwise involved in the trial; 13 of 71 patients allocated to the treatment group and 14 of 69 patients allocated to the control group were lost to follow up and data on these patients were not available for the present analyses. Intention-to-treat analyses were employed in the two fludrocortisone acetate trials (<LINK REF="STD-Hasan-1989" TYPE="STUDY">Hasan 1989</LINK>; <LINK REF="STD-Mori-1999" TYPE="STUDY">Mori 1999</LINK>) only. A double-blind placebo controlled design was used in the hydrocortisone trial by Hashi et al (<LINK REF="STD-Hashi-1988" TYPE="STUDY">Hashi 1988</LINK>) (all outcomes were assessed blindly) while an open control design was used in the fludrocortisone trials. In one of these fludrocortisone trials outcome assessment was blinded (Dr Hasan, personal communication). Antifibrinolytic treatment with tranexamic acid for the first four days after admission was given to all randomised patients in one fludrocortisone acetate trial (<LINK REF="STD-Hasan-1989" TYPE="STUDY">Hasan 1989</LINK>) but not in the other (<LINK REF="STD-Mori-1999" TYPE="STUDY">Mori 1999</LINK>). In the three trials control and treatment groups were well balanced with regard to major prognostic factors (such as age, patients' clinical severity grade on admission, site of aneurysm, and/or the amount of blood on the initial CT scan).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">PICH trials</HEADING>
<P>The trial by Tellez and Bauer (<LINK REF="STD-Tellez-1973" TYPE="STUDY">Tellez 1973</LINK>) was carried out before the era of CT scanning and the diagnosis of intracerebral haemorrhage on admission was based on clinical features and the results of CSF examination. Final diagnosis, based on autopsy or cerebral angiography findings, showed that 29 (72%) of patients included in this trial had PICH and 11 (28%) had ischaemic stroke with haemorrhagic transformation. However, no breakdown of outcomes by final diagnosis was provided in the original publication, therefore, all patients were analysed together. In this trial 17 of 40 patients were randomly allocated to either 'treatment' or 'control' (the exact method of randomisation was not specified in the publication) and the remaining 23 patients were given coded containers containing either dexamethasone or placebo. It is not clear from the original publication whether the outcome assessment was blinded in the 17 randomised patients but in the remaining 23 patients the outcomes were assessed blindly (both active treatment group patients received the same treatment with dexamethasone). The trialists stated that there was no statistical difference between these two patient groups and, therefore, they were combined for analysis; they did not specify what characteristics were assessed. Two of 21 patients in the treatment group were excluded from final analysis because the final diagnosis turned out to be other than PICH. Many prognostic baseline characteristics were not equally distributed between the treatment and control groups: coma or 'deep stupor' on admission was found in 15 of 19 dexamethasone treated patients (79%) and in 12 of 21 patients (57%) allocated to the control group. The exact method of randomisation, blinding of outcome assessment, and baseline characteristics of the treatment groups were not specified in the two small trials (<LINK REF="STD-Hooshmand-1972" TYPE="STUDY">Hooshmand 1972</LINK>; <LINK REF="STD-Ogun-2001" TYPE="STUDY">Ogun 2001</LINK>) but the trialists used intention-to-treat analyses; all patients had angiographically documented PICH in one of the trials (<LINK REF="STD-Hooshmand-1972" TYPE="STUDY">Hooshmand 1972</LINK>). Intention-to-treat analysis was used in a double-blind trial by Desai et al (<LINK REF="STD-Desai-1998" TYPE="STUDY">Desai 1998</LINK>) in which a pharmacy-controlled randomisation procedure was employed. Poungvarin et al (<LINK REF="STD-Poungvarin-1987" TYPE="STUDY">Poungvarin 1987</LINK>) used a double-blind randomised block design by stratifying the patients into three main groups according to their level of consciousness at the time of randomisation. A randomisation scheme controlled by a pharmacy was used to allocate patients to either group (Dr Poungvarin 1996, personal communication). The treatment and control groups were well balanced with regard to major prognostic factors of survival except that the overall size of haematomas (72.4 ml in dexamethasone-treated patients versus 59.6 ml in controls) and the proportion of patients with multiple haematomas (2 of 46 in dexamethasone treated group versus 5 of 47 in controls) were different between the groups.</P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-08-05 13:40:19 +0100" MODIFIED_BY="Hazel Fraser">
<SUBSECTION>
<HEADING LEVEL="3">Corticosteroids in patients with SAH</HEADING>
<P>Since there was only one trial using glucocorticoid treatment with hydrocortisone sodium phosphate (<LINK REF="STD-Hashi-1988" TYPE="STUDY">Hashi 1988</LINK>), and all the outcome measures but two (DCI and 'other adverse effects') were different between the three trials, the pooled effect estimates for hydrocortisone intervention and most of the outcomes cannot be calculated. Mineralocorticoid treatment with fludrocortisone (<LINK REF="STD-Hasan-1989" TYPE="STUDY">Hasan 1989</LINK>; <LINK REF="STD-Mori-1999" TYPE="STUDY">Mori 1999</LINK>) tended to reduce the relative risk (RR) of DCI (RR 0.65; 95% confidence interval (CI) 0.33 to 1.27) and poor outcome (RR 0.33; 95% CI 0.03 to 3.20) but pooled estimates for mineralocorticoids (<LINK REF="STD-Hasan-1989" TYPE="STUDY">Hasan 1989</LINK>) and glucocorticoids (<LINK REF="STD-Hashi-1988" TYPE="STUDY">Hashi 1988</LINK>) showed that these treatments were associated with an increased risk of adverse effects (RR 1.75; 95% CI 1.03 to 2.95), mainly because of the very high risk of hydrocortisone-induced hyperglycaemia in the <LINK REF="STD-Hashi-1988" TYPE="STUDY">Hashi 1988</LINK> trial. In total, treatment with corticosteroids (glucocorticoids (<LINK REF="STD-Hashi-1988" TYPE="STUDY">Hashi 1988</LINK>), and mineralocorticoids (<LINK REF="STD-Mori-1999" TYPE="STUDY">Mori 1999</LINK>)) had no significant effect on poor outcome at the end of follow up (RR 0.96; 95% CI 0.77 to 1.20). No deaths occurred in the mineralocorticoid trials during the follow-up periods. Treatment with glucocorticoids (<LINK REF="STD-Hashi-1988" TYPE="STUDY">Hashi 1988</LINK>) tended to increase one month case fatality (RR 1.49; 95% CI 0.85 to 2.61) but no effect on poor outcome at the end of one month follow up was noted (RR 0.99; 95% CI 0.80 to 1.24). However, findings from this trial do not represent all SAH patients but only a subgroup of SAH patients with a probably more severe natural course of the disease who already suffered from DCI. Apart from the above mentioned hyperglycaemia the most frequent adverse effects of this treatment were arterial hypotension (RR 1.20; 95% CI 0.34 to 4.32) and gastrointestinal bleeding (RR 1.12; 95% CI 0.40 to 3.19). The RR of other adverse effects, such as liver disfunction, electrolyte abnormality, leucopenia, flushing, pruritus, rush, and vasculitis, was 3.53 (95% CI 1.02 to 12.18).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Corticosteroids in patients with PICH</HEADING>
<P>At one month after randomisation 57 of 92 patients (62%) allocated to the glucocorticoid treatment in four trials (<LINK REF="STD-Desai-1998" TYPE="STUDY">Desai 1998</LINK>; <LINK REF="STD-Ogun-2001" TYPE="STUDY">Ogun 2001</LINK>; <LINK REF="STD-Poungvarin-1987" TYPE="STUDY">Poungvarin 1987</LINK>; <LINK REF="STD-Tellez-1973" TYPE="STUDY">Tellez 1973</LINK>) had died compared with 50 of 94 patients (53%) allocated to the control group (RR 1.14; 95% CI 0.91 to 1.42). The <LINK REF="STD-Hooshmand-1972" TYPE="STUDY">Hooshmand 1972</LINK> trial was not included in the analysis of deaths at one month after randomisation because death in this trial was recorded at two weeks and not at one month as in other trials included in the analysis. Treatment with glucocorticoids did not reduce poor outcome at one month after randomisation (RR 0.95; 95% CI 0.83 to 1.09). In one small trial (<LINK REF="STD-Hooshmand-1972" TYPE="STUDY">Hooshmand 1972</LINK>) a 40% reduction in the RR of death at six months of follow up was noticed (RR 0.60; 95% CI 0.19 to 1.86). The site of the PICH (supratentorial, brainstem or mixed) appeared to play no substantial role in the death outcomes. No statistically significant effects on poor outcome at one month of follow up were observed (RR 0.96; 95% CI 0.84 to 1.10). The risk of any adverse effects in the treatment group patients (13%) was 32% higher than that in the control group patients (8.8%) but the confidence interval was very wide (RR 1.48; 95% CI 0.87 to 2.51). The most common side effects of dexamethasone treatment were infections (23%), exacerbation of diabetes mellitus (11%), and gastrointestinal bleeding (5%) but none of them had reached a statistically significant difference between the treatment and control groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analyses</HEADING>
<P>Sensitivity analyses based on random-effects models, exclusion of trials with unspecified methods of randomisation (<LINK REF="STD-Hashi-1988" TYPE="STUDY">Hashi 1988</LINK>; <LINK REF="STD-Mori-1999" TYPE="STUDY">Mori 1999</LINK> for SAH trials; <LINK REF="STD-Hooshmand-1972" TYPE="STUDY">Hooshmand 1972</LINK>; <LINK REF="STD-Ogun-2001" TYPE="STUDY">Ogun 2001</LINK>; <LINK REF="STD-Tellez-1973" TYPE="STUDY">Tellez 1973</LINK> for PICH trials), and PICH trials without CT confirmation of the diagnosis (<LINK REF="STD-Hooshmand-1972" TYPE="STUDY">Hooshmand 1972</LINK>; <LINK REF="STD-Ogun-2001" TYPE="STUDY">Ogun 2001</LINK>; <LINK REF="STD-Tellez-1973" TYPE="STUDY">Tellez 1973</LINK>) did not significantly alter the point estimates of the results. No statistically significant heterogeneity was noticed between either SAH or PICH trials and no evidence of publication bias was detected.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>The number of patients allocated to either hydrocortisone or fludrocortisone acetate treatment in patients with SAH or to dexamethasone treatment in patients with PICH was too small to make any definitive conclusions (very wide confidence intervals were observed for any outcome estimate). Although some trials included in the review analysed the same therapeutic agent (dexamethasone), the studies differed substantially with regard to the populations studied and methodological quality of the study designs. This, together with the small numbers of patients analysed, and no proper confirmation of the diagnosis in some of the PICH trials, suggests that the results of these analyses should be interpreted with caution. Moreover, some specific corticosteroid treatment modes, such as a pulse high-dose treatment at very early stages of primary supratentorial or brain stem intracerebral haemorrhage, have not yet been tested. Overall, there is no evidence of a beneficial or adverse effect of corticosteroids in patients with either SAH or PICH whereas there is some evidence that corticosteroids increase the risk of serious adverse effects. However, confidence intervals were wide and included clinically significant effects in both directions. <BR/>
</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>At present, there is no evidence to support the routine use of corticosteroids (mineralocorticoids or glucocorticoids) in patients with subarachnoid haemorrhage (SAH) or the use of glucocorticoids in patients with primary intracerebral haemorrhage (PICH). Treatment of these patients with corticosteroids may be associated with an increased risk of adverse effects.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Further randomised controlled trials with intention-to-treat design in various clinical settings (e.g. time and dosage of intervention, timing of aneurysm surgery for SAH, pulse high-dose treatment at very early stages of primary supratentorial or brain stem intracerebral haemorrhage) are warranted to evaluate the efficacy and safety of treatment with corticosteroids in these patients. </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>The authors would like to thank Dr K Hashi and Dr D Hasan for providing some additional data for their trials; Dr S Uchiyama for translating the paper by Dr K Hashi et al; and Dr N Poungvarin for providing some additional information regarding his trial design. The authors are also very grateful to Hazel Fraser and Prof Peter Sandercock for their valuable editorial help in writing this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>The authors have no conflict of interest.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>VL Feigin: participated in developing the protocol; retrieving papers; data extraction; appraising the quality of studies; data management; data analysis; data interpretation; writing the review; and entering the review into RevMan. Dr Feigin is the guarantor for this review.</P>
<P>N Anderson: participated in developing the protocol; retrieving papers; data interpretation; and writing the review.</P>
<P>GJE Rinkel: participated in writing the grant application; developing the protocol; data extraction; appraising the quality of studies; data analysis; data interpretation; writing the review.</P>
<P>A Algra: participated in writing the grant application; developing the protocol; data interpretation; and writing the review.</P>
<P>J van Gijn: participated in writing the grant application; developing the protocol; data interpretation; and writing the review.</P>
<P>DA Bennett: participated in developing the protocol; data extraction; appraising the quality of studies; data entering and analysis; data interpretation; and writing the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Desai-1998" NAME="Desai 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Desai P, Prasad K</AU>
<TI>Dexamethasone is not necessarily unsafe in primary supratentorial intracerebral haemorrhage</TI>
<SO>Journal of Neurology, Neurosurgery and Psychiatry</SO>
<YR>1998</YR>
<VL>65</VL>
<NO>5</NO>
<PG>799-800</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hasan-1989" NAME="Hasan 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Hasan D, Lindsay KW, Wijdicks EF, Murray GD, Brouwers PJ, Bakker WH, van Gijn J, Vermeulen M. Effect of fludrocortisone acetate in patients with subarachnoid hemorrhage. Stroke 1989;20:1156-1161.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hasan D, Lindsay KW, Wijdicks EF, Murray GD, Brouwers PJ, Bakker WH, et al</AU>
<TI>Effect of fludrocortisone acetate in patients with subarachnoid hemorrhage</TI>
<SO>Stroke</SO>
<YR>1989</YR>
<VL>20</VL>
<PG>1156-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hashi-1988" NAME="Hashi 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Hashi K, Takakura K, Sano K, Ohta T, Saito I, Okada K. [Intravenous hydrocortisone in large doses in the treatment of delayed ischemic neurological deficits following subarachnoid hemorrhage--results of a multi-center controlled double-blind clinical study]. [Japanese].  No to Shinkei - Brain &amp;amp; Nerve 1988;40:373-382.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hashi K, Takakura K, Sano K, Ohta T, Saito I, Okada K</AU>
<TI>[Intravenous hydrocortisone in large doses in the treatment of delayed ischemic neurological deficits following subarachnoid hemorrhage - results of a multi-center controlled double-blind clinical study] [Japanese]</TI>
<SO>No to Shinkei - Brain &amp; Nerve</SO>
<YR>1988</YR>
<VL>40</VL>
<PG>373-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hooshmand-1972" NAME="Hooshmand 1972" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hooshmand H, Quinn JC, Houff SA</AU>
<TI>Cerebrospinal fluid pressure changes with chemotherapy for intracerebral hemorrhage</TI>
<SO>Neurology</SO>
<YR>1972</YR>
<VL>22</VL>
<PG>56-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mori-1999" NAME="Mori 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mori T, Katayama Y, Kawamata T, Hirayama T</AU>
<TI>Improved efficiency of hypervolemic therapy with inhibition of natriuresis by fludrocortisone in patients with aneurysmal subarachnoid hemorrhage</TI>
<SO>Journal of Neurosurgery</SO>
<YR>1999</YR>
<VL>91</VL>
<PG>947-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ogun-2001" NAME="Ogun 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ogun SA, Odusote KA</AU>
<TI>Effectiveness of high dose dexamethasone in the treatment of acute stroke</TI>
<SO>West African Journal of Medicine</SO>
<YR>2001</YR>
<VL>20</VL>
<NO>1</NO>
<PG>1-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poungvarin-1987" NAME="Poungvarin 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;Poungvarin N, Bhoopat W, Viriyavejakul A, Rodprasert P, Buranasiri P, Sukondhabhant S, Hensley MJ, Strom BL. Effects of dexamethasone in primary supratentorial intracerebral hemorrhage. N Engl J Med 1987;316:1229-1233.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Poungvarin N, Bhoopat W, Viriyavejakul A, Rodprasert P, Buranasiri P, Sukondhabhant S, et al</AU>
<TI>Effects of dexamethasone in primary supratentorial intracerebral hemorrhage</TI>
<SO>New England Journal of Medicine</SO>
<YR>1987</YR>
<VL>316</VL>
<PG>1229-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tellez-1973" NAME="Tellez 1973" YEAR="1973">
<REFERENCE NOTES="&lt;p&gt;Tellez H, Bauer RB. Dexamethasone as treatment in cerebrovascular disease. 1. A controlled study in intracerebral hemorrhage. Stroke 1973;4:541-546.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tellez H, Bauer RB</AU>
<TI>Dexamethasone as treatment in cerebrovascular disease. 1. A controlled study in intracerebral hemorrhage</TI>
<SO>Stroke</SO>
<YR>1973</YR>
<VL>4</VL>
<PG>541-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Wijdicks" NAME="Wijdicks" YEAR="">
<REFERENCE NOTES="&lt;p&gt;EFM Wijdicks, personal communication&lt;/p&gt;" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Wijdicks EFM, Petty GW, Wiebers DO, Whisnant JP, Meyer FB, Ingall TJ, et al</AU>
<TI>High-dose methylprednisolone pulse in supratentorial intracerebral hemorrhage, a randomised double-blind clinical multicenter trial</TI>
<SO>Personal communication</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES>
<STUDY DATA_SOURCE="UNPUB" ID="STD-STICH_x002d_Pilot-2004" NAME="STICH-Pilot 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Lalonde DR</AU>
<TI>Steroid Treatment for IntraCerebral Hemorrhage (STICH)</TI>
<SO>Unpublished</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Bauer-1973" NAME="Bauer 1973" TYPE="JOURNAL_ARTICLE">
<AU>Bauer RB, Tellez H</AU>
<TI>Dexamethasone as treatment in cerebrovascular disease. 2. A controlled study in acute cerebral infarction</TI>
<SO>Stroke</SO>
<YR>1973</YR>
<VL>4</VL>
<PG>547-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Beldman-1996" NAME="Beldman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Beldman TFJ, Rinkel GJE, Algra A</AU>
<TI>Prediction of long term outcome after primary intracerebral haemorrhage: the importance of the site of the lesion</TI>
<SO>Cerebrovascular Disease</SO>
<YR>1997</YR>
<VL>7</VL>
<NO>2</NO>
<PG>85-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brouwers-1993" NAME="Brouwers 1993" TYPE="JOURNAL_ARTICLE">
<AU>Brouwers PJAM, Dippel DWJ, Vermeulen M, Lindsay KW, Hasan D, van Gijn J</AU>
<TI>Amount of blood on computed tomography as an independent predictor after aneurysm rupture</TI>
<SO>Stroke</SO>
<YR>1993</YR>
<VL>24</VL>
<PG>809-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chyatte-1983" NAME="Chyatte 1983" TYPE="JOURNAL_ARTICLE">
<AU>Chyatte D, Rusch N, Sundt TM Jr</AU>
<TI>Prevention of chronic experimental cerebral vasospasm with ibuprofen and high-dose methylprednisolone</TI>
<SO>Journal of Neurosurgery</SO>
<YR>1983</YR>
<VL>59</VL>
<PG>925-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chyatte-1987" NAME="Chyatte 1987" TYPE="JOURNAL_ARTICLE">
<AU>Chyatte D, Fode NC, Nichols DA, Sundt TM Jr</AU>
<TI>Preliminary report: effects of high dose methylprednisolone on delayed cerebral ischemia in patients at high risk for vasospasm after aneurysmal subarachnoid hemorrhage</TI>
<SO>Neurosurgery</SO>
<YR>1987</YR>
<VL>21</VL>
<PG>157-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clasen-1980" NAME="Clasen 1980" TYPE="JOURNAL_ARTICLE">
<AU>Clasen RA, Huckman MS, Von Roenn KA, Pandolfi S, Laing I, Clasen JR</AU>
<TI>Time course of cerebral swelling in stroke: a correlative autopsy and CT study</TI>
<SO>Advances in Neurology</SO>
<YR>1980</YR>
<VL>28</VL>
<PG>395-412</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-De-Reuck-1989" NAME="De Reuck 1989" TYPE="JOURNAL_ARTICLE">
<AU>De Reuck J, De Bleecker J, Reyntjens K</AU>
<TI>Steroid treatment in primary intracerebral haemorrhage</TI>
<SO>Acta Neurologica Belgica</SO>
<YR>1989</YR>
<VL>89</VL>
<PG>7-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Feigin-2003" NAME="Feigin 2003" TYPE="JOURNAL_ARTICLE">
<AU>Feigin VL, Lawes CMM, Bennett DA, Anderson CS</AU>
<TI>Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century</TI>
<SO>Lancet Neurology</SO>
<YR>2003</YR>
<VL>2</VL>
<PG>43-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fox-1975" NAME="Fox 1975" TYPE="JOURNAL_ARTICLE">
<AU>Fox JL, Yasargil MG</AU>
<TI>The relief of intracranial vasospasm: an experimental study with methylprednisolone and cortisol</TI>
<SO>Surgical Neurology</SO>
<YR>1975</YR>
<VL>3</VL>
<PG>214-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Handbook-2004" NAME="Handbook 2004" TYPE="OTHER">
<AU>Alderson P, Green S, Higgins JPT, editors</AU>
<TI>Cochrane Reviewers' Handbook 4.2.3 [updated November 2004]</TI>
<SO>In: The Cochrane Library, Issue 1, 2005. Chichester, UK: John Wiley &amp; Sons, Ltd</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hashi-1980" NAME="Hashi 1980" TYPE="BOOK_SECTION">
<AU>Hashi K, Matsuoka Y, Tanaka K, Ohkawa N</AU>
<TI>Treatment of cerebral vasospasm with large doses of hydrocortisone</TI>
<SO>Cerebral Arterial Spasm</SO>
<YR>1980</YR>
<ED>Wilkins RH</ED>
<PB>Williams &amp; Wilkins</PB>
<CY>Baltimore</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hedges-1994" NAME="Hedges 1994" TYPE="BOOK_SECTION">
<AU>Hedges LV</AU>
<TI>Statistical considerations</TI>
<SO>The Handbook of Research Synthesis</SO>
<YR>1994</YR>
<PG>30-33</PG>
<ED>Cooper H, Hedges LV</ED>
<PB>Russell Sage Foundation</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hijdra-1988" NAME="Hijdra 1988" TYPE="JOURNAL_ARTICLE">
<AU>Hijdra A, van Gijn J, Nagelkerke NJ, Vermeulen M, van Crevel H</AU>
<TI>Prediction of delayed cerebral ischemia, rebleeding, and outcome after aneurysmal subarachnoid hemorrhage</TI>
<SO>Stroke</SO>
<YR>1988</YR>
<VL>19</VL>
<PG>1250-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hop-1997" NAME="Hop 1997" TYPE="JOURNAL_ARTICLE">
<AU>Hop JW, Rinkel GJE, Algra A, van Gijn J.</AU>
<TI>Case-fatality rates and functional outcome after subarachnoid hemorrhage: a systematic review</TI>
<SO>Stroke</SO>
<YR>1997</YR>
<VL>28</VL>
<NO>3</NO>
<PG>660-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hop-1999" NAME="Hop 1999" TYPE="JOURNAL_ARTICLE">
<AU>Hop JW, Rinkel GJ, Algra A, van Gijn J</AU>
<TI>Initial loss of consciousness and risk of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage</TI>
<SO>Stroke</SO>
<YR>1999</YR>
<VL>30</VL>
<PG>2268-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ischii-1979" NAME="Ischii 1979" TYPE="JOURNAL_ARTICLE">
<AU>Ischii R</AU>
<TI>Regional cerebral blood flow in patients with ruptured intracranial aneurysms</TI>
<SO>Journal of Neurosurgery</SO>
<YR>1979</YR>
<VL>50</VL>
<PG>587-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al</AU>
<TI>Assessing the quality of reports of randomised clinical trials: is blinding necessary?</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<NO>1</NO>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Karnik-1990" NAME="Karnik 1990" TYPE="JOURNAL_ARTICLE">
<AU>Karnik R, Valentin A, Prainer C, Stollberger C, Slany J</AU>
<TI>Steroid therapy in subarachnoid hemorrhage (German)</TI>
<SO>Wiener Klinische Wochenschrift</SO>
<YR>1990</YR>
<VL>102</VL>
<NO>1</NO>
<PG>1-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kase-1991" NAME="Kase 1991" TYPE="JOURNAL_ARTICLE">
<AU>Kase CS</AU>
<TI>Diagnosis and management of intracerebral hemorrhage in elderly patients</TI>
<SO>Clinics in Geriatric Medicine</SO>
<YR>1991</YR>
<VL>7</VL>
<NO>3</NO>
<PG>549-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ljunggren-1983" NAME="Ljunggren 1983" TYPE="JOURNAL_ARTICLE">
<AU>Ljunggren B, Saveland H, Brandt L</AU>
<TI>Causes of unfavourable outcome after early aneurysm operation</TI>
<SO>Neurosurgery</SO>
<YR>1983</YR>
<VL>13</VL>
<PG>629-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Longstreth-1993" NAME="Longstreth 1993" TYPE="JOURNAL_ARTICLE">
<AU>Longstreth WT Jr, Nelson LM, Koepsell TD, et al</AU>
<TI>Clinical course of spontaneous subarachnoid hemorrhage: a population-based study in King County, Washington</TI>
<SO>Neurology</SO>
<YR>1993</YR>
<VL>43</VL>
<PG>712-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Meyer-1995" NAME="Meyer 1995" TYPE="JOURNAL_ARTICLE">
<AU>Meyer FB, Morita A, Puumala MR, Nichols DA</AU>
<TI>Medical and surgical management of intracranial aneurysms</TI>
<SO>Mayo Clinic Proceedings</SO>
<YR>1995</YR>
<VL>70</VL>
<PG>153-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Norris-1976" NAME="Norris 1976" TYPE="JOURNAL_ARTICLE">
<AU>Norris JW</AU>
<TI>Steroid therapy in acute cerebral infarction</TI>
<SO>Archives of Neurology</SO>
<YR>1976</YR>
<VL>33</VL>
<PG>69-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Olkin-1995" NAME="Olkin 1995" TYPE="JOURNAL_ARTICLE">
<AU>Olkin I</AU>
<TI>Statistical and theoretical considerations in meta-analysis</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>1995</YR>
<VL>48</VL>
<PG>133-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thompson-2002" NAME="Thompson 2002" TYPE="JOURNAL_ARTICLE">
<AU>Thompson SG, Higgins JPT</AU>
<TI>How should meta-regression analyses be undertaken and interpreted</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>1559-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wijdicks-1985" NAME="Wijdicks 1985" TYPE="JOURNAL_ARTICLE">
<AU>Wijdicks EFM, Vermeulen M, Ten Haaf JA, Bakker WH, van Gijn J</AU>
<TI>Volume depletion and natriuresis in patients with a ruptured intracranial aneurysm</TI>
<SO>Annals of Neurology</SO>
<YR>1985</YR>
<VL>18</VL>
<PG>211-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wijdicks-1988a" NAME="Wijdicks 1988a" TYPE="JOURNAL_ARTICLE">
<AU>Wijdicks EFM, van Dongen KJ, van Gijn J, Hijdra A, Vermeulen M</AU>
<TI>Enlargement of the third ventricle and hyponatraemia in aneurysmal subarachnoid haemorrhage</TI>
<SO>Journal of Neurology, Neurosurgery and Psychiatry</SO>
<YR>1988</YR>
<VL>51</VL>
<PG>516-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wijdicks-1988b" NAME="Wijdicks 1988b" TYPE="JOURNAL_ARTICLE">
<AU>Wijdicks EFM, Vermeulen M, van Brummelen P, van Gijn J</AU>
<TI>The effect of fludrocortisone acetate on plasma volume and natriuresis in aneurysmal subarachnoid haemorrhage</TI>
<SO>Clinical Neurology &amp; Neurosurgery</SO>
<YR>1988</YR>
<VL>90</VL>
<PG>209-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yamakawa-1991" NAME="Yamakawa 1991" TYPE="JOURNAL_ARTICLE">
<AU>Yamakawa K, Sasaki T, Tsubaki S, Nakagomi T, Saito I, Takakura K</AU>
<TI>Effect of high-dose methylprednisolone on vasospasm after subarachnoid hemorrhage</TI>
<SO>Neurologia Medico Chirurgica (Tokyo)</SO>
<YR>1991</YR>
<VL>31</VL>
<PG>24-31</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Desai-1998">
<CHAR_METHODS>
<P>Method of randomisation: controlled by pharmacy.<BR/>Blinding: double blind.<BR/>Analysis: intention-to-treat.<BR/>Definition of outcomes: stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Location: All India Institute of Medical Sciences.<BR/>Rx: 12 patients (gender not stated).<BR/>Controls: 14 patients (gender not stated).<BR/>Age range: 40-80.<BR/>Entry criteria: CT scan confirmed primary supratentorial intracerebral haemorrhage within 5 days of onset.<BR/>Comparability of treatment groups: there were more comatose patients in Rx group (5/12) than in the placebo group (3/14), but well comparable for other major prognostic factors.<BR/>Exclusion criteria: previous disabling stroke, contraindications to steroids.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Rx: dexamethasone 4 mg IV QID for 12 days, 4 mg IV BD for 2 days, then 2 mg IV BD for 2 days.<BR/>Controls: matched placebo (saline) for 16 days.<BR/>All patients received ranitidine for the period of the trial.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death, vegetative state, dependency (Glasgow outcome score).<BR/>Follow-up duration: 7 days and at discharge.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Complications and possible adverse effects: infections, gastrointestinal bleeding, diabetogenic effect.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hasan-1989">
<CHAR_METHODS>
<P>Method of randomisation: random number tables by means of a sealed envelope technique stratified per center; open controls design.<BR/>Blinding: blinded outcome assessment.<BR/>Analysis: intention-to-treat analysis.<BR/>Losses to follow up: none.<BR/>Definition of outcomes: stated.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Location: Royal Free Hospital, London (UK); University Hospital Rotterdam and University Hospital Utrecht (The Netherlands).<BR/>Rx: 46.<BR/>Controls: 45.<BR/>Sex: males/females.<BR/>Mean age: 50 years.<BR/>Entry criteria: CT scan or CSF examination confirmed SAH.<BR/>Comparability of the treatment groups: well matched with regard to sex, age, hours to entry, severity grades, proportion of aneurysm and the amount of cisternal/intraventricular blood on the initial CT, fluid and sodium intake.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Rx: fludrocortisone acetate intravenously or orally 400 microgram/day in two doses, for a maximum duration of 12 days.<BR/>Controls: no corticosteroid treatment.<BR/>All patients: tranexamic acid intravenously for the first 4 days after admission, in 6 doses of 1g/day; fluid intake was maintained at 3 l/day either orally or IV (isotonic saline). Treatment with anticoagulants, platelet antiaggregants, and diuretics was prohibited during the study period.<BR/>Timing of surgery: surgery was planned between days 7 and 10 in London and on day 12 in Rotterdam and Utrecht.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Glasgow Outcome Scale at one month of follow up. Probable DCI (gradual development of focal neurologic signs, with or without deterioration in the level of consciousness, without confirmation by CT scan or autopsy) and definite DCI (gradual or sudden deterioration in the level of consciousness, or the development of focal signs, or both, with CT scan or autopsy confirmation of cerebral infarction).<BR/>Additional measurements: total plasma volume, cumulative sodium and fluid balances.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Follow-up duration: 28 days for clinical outcomes and 12 days for additional measurements.<BR/>Exclusion criteria: a lapse of &gt;72 hours since the onset of SAH; age of &gt;70 years; previous treatment with diuretics or corticosteroids; presence of endocrine, renal, or cardiac disease; or CT evidence of a cause for the SAH other than aneurysm.<BR/>Adverse effects: pulmonary oedema, hypokalemia, blood pressure changes.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hashi-1988">
<CHAR_METHODS>
<P>Method of randomisation: done by a controller (exact method not specified).<BR/>Blinding: double-blind design.<BR/>Analysis: protocol analysis.<BR/>Losses to follow up: 13 cases and 14 controls.<BR/>Definition of outcomes: stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Location: 52 institutes in Japan.<BR/>Rx: 71.<BR/>Controls: 69.<BR/>Sex: males/females.<BR/>Age range: &gt;20 years.<BR/>Entry criteria: patients with aneurysmal SAH who suffered from DCI due to vasospasm.<BR/>Exclusion criteria: patients with Hunt and Hess severity grade V.<BR/>Comparability of treatment groups: well matched with regard to age, sex, site of aneurysm, mean blood pressure, and severity grade at admission, and interval between DCI and start of drug administration.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Rx: hydrocortisone sodium phosphate (3 g in a 60 ml solution) intraveneously 6 times with interval of 12 hours.<BR/>Controls: placebo (folic acid 0.1 mg/ml in the same solvent identical in colour to hydrocortisone sodium phosphate) intravenously 6 times with interval of 12 hours.<BR/>Prophylactic use of anti-peptic ulcer agents was allowed in all patients; insulin was given when the blood glucose level rose.<BR/>Timing of surgery: 42% of Rx and 46% of controls were operated on within the first 2 days of SAH onset; 41% of cases and 26% of controls were operated on between day 3 and 9 of SAH onset; interval between SAH and surgery was over 10 days in 15% of cases and 13% of controls.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Clinical outcomes: delayed ischaemic neurological deficit, level of consciousness, mental/speech and motor functions, activity of daily living.<BR/>Additional measurements: side effects of the treatment such as blood glucose level, mean blood pressure level, serum sodium and potassium levels.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Follow-up duration: 1 month.<BR/>Adverse effects: hyperglycemia, gastrointestinal bleeding, hypotension, liver dysfunction, electrolyte abnormality.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hooshmand-1972">
<CHAR_METHODS>
<P>Method of randomisation: not stated.<BR/>Blinding: not stated but likely unblinded.<BR/>Analysis: intention-to-treat analysis.<BR/>Losses to follow up: none.<BR/>Definition of outcomes: stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Location: Virginia Commonwealth University, Richmond, USA.<BR/>Rx: 10.<BR/>Controls: 10.<BR/>Sex and age range: not specified.<BR/>Entry criteria: patients angiographically documented PICH.<BR/>Exclusion criteria: not stated.<BR/>Comparability of treatment groups: not specified.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Rx: dexamethasone IM (6 mg) every 4 hours for 10 days.<BR/>Controls: no treatment with dexamethasone.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Alertness levels, death.<BR/>Follow-up duration: 2 weeks and 3 to 6 months.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Complication and possible adverse effects: not reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Mori-1999">
<CHAR_METHODS>
<P>Method of randomisation: not stated.<BR/>Blinding: not stated.<BR/>Analysis: intention-to-treat analysis.<BR/>Losses to follow up: none.<BR/>Definition of outcomes: stated.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Location: Nihon University School of Medicine, Tokyo, Japan. <BR/>Rx: 15.<BR/>Controls: 10.<BR/>Sex: males/females.<BR/>Mean age: 56 years.<BR/>Entry criteria: ruptured and clipped intracranial aneurysms within 2 days of onset.<BR/>Comparability of the treatment groups: well matched with regard to sex, age, and severity grades.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Rx: fludrocortisone acetate orally or via nasogastric tube 0.3 mg/day 1-8 days post SAH. <BR/>Controls: no corticosteroid treatment.<BR/>All patients: central venous pressure maintained at 8-12 cm H2O by hypervolaemic therapy with saline IV.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Glasgow Outcome Scale at six months of follow up.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Follow-up duration: 6 months for clinical outcomes and 14 days for additional measurements.<BR/>Exclusion criteria: head trauma, known endocrine disturbances, renal disease, congestive heart failure, intracerebral haematoma &gt;3 cm in diameter by CT scan.<BR/>Complications and possible adverse effects: not reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Ogun-2001">
<CHAR_METHODS>
<P>Method of randomisation: not stated.<BR/>Blinding: not stated.<BR/>Anaysis: intention-to-treat analysis.<BR/>Losses to follow up: none.<BR/>Definition of outcomes: stated.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Location: Lagos University Teaching Hospital, Lagos.<BR/>Rx: 15.<BR/>Controls: 12.<BR/>Sex: males/females.<BR/>Mean age: 56 years.<BR/>Entry criteria: clinically diagnosed PICH within 24 hours of onset.<BR/>Comparability of the treatment groups: well comparable with regard to age and gender, delay to admission and duration of the treatment.<BR/>Exclusion criteria: diabetes mellitus, sepsis at entry, brainstem stroke, commencement of dexamethasone from referral hospital, previous stroke in the same hemisphere, history of recent head injury, SAH, no impairment of consciousness.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Rx: 100 mg of dexamethasone stat, and 16 mg every 6 hours thereafter for 48 hours.<BR/>Controls: equivalent volumes of placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death, neurological recovery at one and two and four months, cause of death.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Duration of follow up: four months.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Poungvarin-1987">
<CHAR_METHODS>
<P>Method of randomisation: double-blind randomised block design (randomisation scheme controlled by pharmacy).<BR/>Blinding: double-blind treatment.<BR/>Analysis: intention-to-treat.<BR/>Definition of outcomes: stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Location: Siriraj Hospital Medical School (Bangkok), Thailand.<BR/>Rx: 23 males and 23 females.<BR/>Controls: 25 males and 22 females.<BR/>Age range: 40-80.<BR/>Entry criteria: patients aged 40-80 years with CT scan documented PICH who admitted to the hospital within 48 hours after the ictus.<BR/>Comparability of treatment groups: well comparable for major prognostic factors.<BR/>Exclusion criteria: haemorrhagic infarction; secondary supratentorial intracerebral haemorrhage due to a parasitic infection; history of peptic ulcer; past history of stroke; arteriovenous malformation; bleeding disorder; ingestion of anticoagulant drugs within 7 days; recent trauma; clinically apparent infection, or a neoplasm.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Rx: dexamethasone IV (10 mg initially and followed by 5 mg every six hours for six days, 5 mg every 12 hours for two days, and 5 mg for one day).<BR/>Controls: matched placebo (saline) for 9 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Good recovery, severe disability, vegetative state, death.<BR/>Follow-up duration: 21 days.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Complications and possible adverse effects: infections, gastrointestinal bleeding, diabetogenic effect.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Tellez-1973">
<CHAR_METHODS>
<P>Method of randomisation: not specified.<BR/>Blinding: not specified.<BR/>Analysis: protocol analysis.<BR/>Losses to follow up: 2 patients on dexamethasone treatment who were excluded from the analysis because the admitting diagnosis was in error.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Location: Wayne State University School of Medicine, Detroit, Michigan, USA.<BR/>Rx: 19. Controls: 21.<BR/>Sex: 25 males and 15 females.<BR/>Mean age: 62 years.<BR/>Entry criteria: clinical evidence of acute intracerebral haemorrhage due to either hypertension, haemorrhagic infarction or cerebral aneurysm (the diagnosis had to be made within 48 hours after the ictus); impairment of the level of consciousness; more than 200 RBCs per microlitre in the CSF; and the absence of history of gastrointestinal bleeding or symptomatic duodenal ulcer.<BR/>Comparability of treatment groups: unfavorable prognostic factors for surviving in the treatment group patients are more prominent than that in the control group patients.<BR/>Exclusion criteria: traumatic intracranial haemorrhage, SAH without neurological deficit.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Rx: dexamethasone (12 mg IV initially and followed by 4 mg IM every 6 hours for 3 days, 4 mg IM every 8 hours for 3 days, 4 mg IM every 12 hours for 2 days, 4 mg IM every 24 hours for 2 days) and supportive therapy.<BR/>Controls: matched placebo for 10 days and supportive therapy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death, neurological status (cranial nerve function, motor system function, speech and mentation), gastrointestinal bleeding, CSF pressure.<BR/>Follow-up duration: 14 days.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Complications and possible adverse effects: gastrointestinal bleeding.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>Adequate allocation concealment (code A) defined as the following: centralised randomisation by telephone; randomisation scheme controlled by pharmacy; randomisation with numbered or coded containers administered sequentially to enrolled participants; randomisation with on site computer system which can only be accessed after entering the characteristics of an enrolled participant; randomisation with sequentially numbered sealed opaque envelopes; and randomisation with sealed envelopes but not sequentially numbered or opaque.<BR/>BD: twice daily<BR/>CSF: cerebrospinal fluid<BR/>CT: computed tomography<BR/>DCI: delayed cerebral ischaemia<BR/>IM: intramuscular<BR/>IV: intravenous<BR/>PICH: primary intracerebral haemorrhage<BR/>QID: four times a day<BR/>RBCs: red blood cells <BR/>Rx: treatment<BR/>SAH: subarachnoid haemorrhage<BR/>Unclear allocation concealment (code B): referred to cases where there was a reason to believe that the allocation concealment was adequate (as stated by the authors of the original publication) but the exact method of the randomisation was not specified sufficiently enough to be regarded as adequate.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Wijdicks">
<CHAR_REASON_FOR_EXCLUSION>
<P>The trial was terminated prematurely because of poor recruitment and lack of interest by investigators (E Wijdicks, personal communication).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR STUDY_ID="STD-STICH_x002d_Pilot-2004">
<CHAR_STUDY_NAME>
<P>Steroid Treatment for IntraCerebral Hemorrhage (STICH).</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Patients with recent (8 hours of onset) supratentorial PICH verified by CT/MRI scanning with no evidence of herniation.<BR/>Rx: 25.<BR/>Controls: 25.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Methylprednisone 30 mg/kg bolus IV then 5.4 mg/kg/hr for 48 hrs vs placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death at 30 days, Barthel Index at 90 days.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Not known.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Dr Daniel R Lalonde<BR/>Fellow, Cerebrovascular Disease<BR/>Department of Medicine (Neurology), University of Texas Health Science Center,<BR/>7703 Floyd Curl Drive,<BR/>San Antonio, Texas 78284-7883.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<FOOTNOTES>
<P>CT: computed tomography<BR/>IV: intravenous<BR/>MRI: magnetic resonance imaging<BR/>PICH: primary intracerebral haemorrhage<BR/>Rx: treatment</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Desai-1998">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Hasan-1989">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Hashi-1988">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hooshmand-1972">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Mori-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ogun-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Poungvarin-1987">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Tellez-1973">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Mineralocorticoid treatment versus control in SAH</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Death at the end of follow up</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>At one month</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>After one to six months</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>At six months</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.2045099580700085" CI_START="0.03467335491696534" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.5057616254997814" LOG_CI_START="-1.4600041349391062" LOG_EFFECT_SIZE="-0.4771212547196625" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.34138810212716" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="15" TOTAL_2="10" WEIGHT="100.00000000000001" Z="0.951426150896346">
<NAME>Poor outcome at the end of follow up</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>At one month</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>After one to six months</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.2045099580700085" CI_START="0.03467335491696534" DF="0.0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="0.5057616254997814" LOG_CI_START="-1.4600041349391062" LOG_EFFECT_SIZE="-0.4771212547196625" NO="3" P_CHI2="1.0" P_Z="0.34138810212716" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="10" WEIGHT="100.00000000000001" Z="0.951426150896346">
<NAME>At six months</NAME>
<DICH_DATA CI_END="3.204509958070007" CI_START="0.03467335491696534" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.5057616254997813" LOG_CI_START="-1.4600041349391062" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="25965" O_E="0.0" SE="1.1547005383792515" STUDY_ID="STD-Mori-1999" TOTAL_1="15" TOTAL_2="10" VAR="1.3333333333333333" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.47546939792132537" CI_END="1.2739831344766461" CI_START="0.3279301057590138" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6463570406703454" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.10516367866478699" LOG_CI_START="-0.4842187109157896" LOG_EFFECT_SIZE="-0.18952751612550128" METHOD="MH" NO="3" P_CHI2="0.490481730330399" P_Q="0.0" P_Z="0.20747824042471352" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="61" TOTAL_2="55" WEIGHT="100.0" Z="1.260530047223382">
<NAME>Delayed cerebral ischaemia during the scheduled treatment or follow-up period</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4067836631108754" CI_START="0.34707711321856355" EFFECT_SIZE="0.6987577639751553" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.14822731624001792" LOG_CI_START="-0.4595740234089547" LOG_EFFECT_SIZE="-0.1556733535844684" ORDER="25966" O_E="0.0" SE="0.35702551557496087" STUDY_ID="STD-Hasan-1989" TOTAL_1="46" TOTAL_2="45" VAR="0.1274672187715666" WEIGHT="88.8412017167382"/>
<DICH_DATA CI_END="5.1236933584781585" CI_START="0.010249903231271793" EFFECT_SIZE="0.22916666666666666" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7095831303025818" LOG_CI_START="-1.9892802347373062" LOG_EFFECT_SIZE="-0.6398485522173621" ORDER="25967" O_E="0.0" SE="1.585325700213548" STUDY_ID="STD-Mori-1999" TOTAL_1="15" TOTAL_2="10" VAR="2.5132575757575757" WEIGHT="11.158798283261802"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="46" TOTAL_2="45" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects of the treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Hypokalemia</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Hyperglycemia</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.04.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Any infection</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.04.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Exacerbation of diabetes mellitus</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.04.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Blood pressure changes</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.04.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Gastrointestinal bleeding</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-001.04.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="46" TOTAL_2="45" WEIGHT="0.0" Z="0.0">
<NAME>Other</NAME>
<DICH_DATA CI_END="6.648688139857462" CI_START="0.14393731647383476" EFFECT_SIZE="0.9782608695652174" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8227359626227094" LOG_CI_START="-0.8418265984351703" LOG_EFFECT_SIZE="-0.009545317906230389" ORDER="25968" O_E="0.0" SE="0.9777722880829642" STUDY_ID="STD-Hasan-1989" TOTAL_1="46" TOTAL_2="45" VAR="0.9560386473429952" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Glucocorticoid treatment versus control in SAH</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.608140223595746" CI_START="0.85138050403051" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4901408450704225" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.41633093702030133" LOG_CI_START="-0.06987629906011793" LOG_EFFECT_SIZE="0.17322731898009167" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.16253290836219375" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="71" TOTAL_2="69" WEIGHT="100.0" Z="1.3966032635649814">
<NAME>Death at the end of follow up</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.608140223595746" CI_START="0.85138050403051" DF="0.0" EFFECT_SIZE="1.4901408450704225" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="15" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.41633093702030133" LOG_CI_START="-0.06987629906011793" LOG_EFFECT_SIZE="0.17322731898009167" NO="1" P_CHI2="1.0" P_Z="0.16253290836219375" STUDIES="1" TAU2="0.0" TOTAL_1="71" TOTAL_2="69" WEIGHT="100.0" Z="1.3966032635649814">
<NAME>At one month</NAME>
<DICH_DATA CI_END="2.608140223595746" CI_START="0.85138050403051" EFFECT_SIZE="1.4901408450704225" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="15" LOG_CI_END="0.41633093702030133" LOG_CI_START="-0.06987629906011793" LOG_EFFECT_SIZE="0.17322731898009167" ORDER="25969" O_E="0.0" SE="0.28560053723827267" STUDY_ID="STD-Hashi-1988" TOTAL_1="71" TOTAL_2="69" VAR="0.08156766687078996" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>After one to six months</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>At six months</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2369039181634172" CI_START="0.7957107109847523" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9920774647887324" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="48" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.09233596524586214" LOG_CI_START="-0.09924479590364918" LOG_EFFECT_SIZE="-0.0034544153288935337" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.9436518942126689" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="71" TOTAL_2="69" WEIGHT="100.0" Z="0.07068068413185426">
<NAME>Poor outcome at the end of follow up</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2369039181634172" CI_START="0.7957107109847523" DF="0.0" EFFECT_SIZE="0.9920774647887324" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="48" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="0.09233596524586214" LOG_CI_START="-0.09924479590364918" LOG_EFFECT_SIZE="-0.0034544153288935337" NO="1" P_CHI2="1.0" P_Z="0.9436518942126689" STUDIES="1" TAU2="0.0" TOTAL_1="71" TOTAL_2="69" WEIGHT="100.0" Z="0.07068068413185426">
<NAME>At one month</NAME>
<DICH_DATA CI_END="1.2369039181634172" CI_START="0.7957107109847523" EFFECT_SIZE="0.9920774647887324" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="48" LOG_CI_END="0.09233596524586214" LOG_CI_START="-0.09924479590364918" LOG_EFFECT_SIZE="-0.0034544153288935337" ORDER="25970" O_E="0.0" SE="0.11253548743928524" STUDY_ID="STD-Hashi-1988" TOTAL_1="71" TOTAL_2="69" VAR="0.012664235933197524" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>After one to six months</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.02.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>At six months</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Delayed cerebral ischaemia during the scheduled treatment or follow-up period</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="52" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="324" TOTAL_2="312" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects of the treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Hypokalemia</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="29" EVENTS_2="16" I2="0.0" ID="CMP-002.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="81" TOTAL_2="78" WEIGHT="0.0" Z="0.0">
<NAME>Hyperglycemia</NAME>
<DICH_DATA CI_END="2.9511943306541966" CI_START="1.0322321705909219" EFFECT_SIZE="1.7453703703703705" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="16" LOG_CI_END="0.46999780792491286" LOG_CI_START="0.013777390184811096" LOG_EFFECT_SIZE="0.24188759905486196" ORDER="25971" O_E="0.0" SE="0.26798613170802543" STUDY_ID="STD-Hashi-1988" TOTAL_1="81" TOTAL_2="78" VAR="0.07181656678783116" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.04.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Any infection</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-002.04.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Exacerbation of diabetes mellitus</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="4" I2="0.0" ID="CMP-002.04.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="81" TOTAL_2="78" WEIGHT="0.0" Z="0.0">
<NAME>Blood pressure changes</NAME>
<DICH_DATA CI_END="4.318437157070631" CI_START="0.3355155010042713" EFFECT_SIZE="1.2037037037037037" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6353266040226754" LOG_CI_START="-0.47428741038290123" LOG_EFFECT_SIZE="0.08051959681988707" ORDER="25972" O_E="0.0" SE="0.6517927647397918" STUDY_ID="STD-Hashi-1988" TOTAL_1="81" TOTAL_2="78" VAR="0.4248338081671415" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="6" I2="0.0" ID="CMP-002.04.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="81" TOTAL_2="78" WEIGHT="0.0" Z="0.0">
<NAME>Gastrointestinal bleeding</NAME>
<DICH_DATA CI_END="3.194929185840521" CI_START="0.395049494326258" EFFECT_SIZE="1.123456790123457" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.5044612366604514" LOG_CI_START="-0.40334848977556365" LOG_EFFECT_SIZE="0.05055637344244389" ORDER="25973" O_E="0.0" SE="0.533251927039135" STUDY_ID="STD-Hashi-1988" TOTAL_1="81" TOTAL_2="78" VAR="0.284357617690951" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="11" EVENTS_2="3" I2="0.0" ID="CMP-002.04.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="81" TOTAL_2="78" WEIGHT="0.0" Z="0.0">
<NAME>Other</NAME>
<DICH_DATA CI_END="12.178846178750268" CI_START="1.0236603532408335" EFFECT_SIZE="3.5308641975308643" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" LOG_CI_END="1.0856061452805938" LOG_CI_START="0.01015588322019266" LOG_EFFECT_SIZE="0.5478810142503933" ORDER="25974" O_E="0.0" SE="0.6317248074989343" STUDY_ID="STD-Hashi-1988" TOTAL_1="81" TOTAL_2="78" VAR="0.3990762324095657" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Corticosteroid treatment versus control in SAH</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.608140223595746" CI_START="0.85138050403051" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4901408450704225" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.41633093702030133" LOG_CI_START="-0.06987629906011793" LOG_EFFECT_SIZE="0.17322731898009167" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.16253290836219375" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="71" TOTAL_2="69" WEIGHT="100.0" Z="1.3966032635649814">
<NAME>Death at the end of follow up</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.608140223595746" CI_START="0.85138050403051" DF="0.0" EFFECT_SIZE="1.4901408450704225" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="15" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="0.41633093702030133" LOG_CI_START="-0.06987629906011793" LOG_EFFECT_SIZE="0.17322731898009167" NO="1" P_CHI2="1.0" P_Z="0.16253290836219375" STUDIES="1" TAU2="0.0" TOTAL_1="71" TOTAL_2="69" WEIGHT="100.0" Z="1.3966032635649814">
<NAME>At one month</NAME>
<DICH_DATA CI_END="2.608140223595746" CI_START="0.85138050403051" EFFECT_SIZE="1.4901408450704225" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="15" LOG_CI_END="0.41633093702030133" LOG_CI_START="-0.06987629906011793" LOG_EFFECT_SIZE="0.17322731898009167" ORDER="25975" O_E="0.0" SE="0.28560053723827267" STUDY_ID="STD-Hashi-1988" TOTAL_1="71" TOTAL_2="69" VAR="0.08156766687078996" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>After one to six months</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>At six months</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9203648968854753" CI_END="1.2007001590620325" CI_START="0.769359774702055" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9611297539149888" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="50" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.07943456816664819" LOG_CI_START="-0.11387052413995774" LOG_EFFECT_SIZE="-0.01721797798665477" METHOD="MH" NO="2" P_CHI2="0.33737932141516613" P_Q="0.0" P_Z="0.7269737482882328" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="86" TOTAL_2="79" WEIGHT="100.00000000000001" Z="0.34915393420593904">
<NAME>Poor outcome at the end of follow up</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2369039181634172" CI_START="0.7957107109847523" DF="0.0" EFFECT_SIZE="0.9920774647887324" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="48" I2="0.0" ID="CMP-003.02.01" LOG_CI_END="0.09233596524586214" LOG_CI_START="-0.09924479590364918" LOG_EFFECT_SIZE="-0.0034544153288935337" NO="1" P_CHI2="1.0" P_Z="0.9436518942126689" STUDIES="1" TAU2="0.0" TOTAL_1="71" TOTAL_2="69" WEIGHT="95.3020134228188" Z="0.07068068413185426">
<NAME>At one month</NAME>
<DICH_DATA CI_END="1.2369039181634172" CI_START="0.7957107109847523" EFFECT_SIZE="0.9920774647887324" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="48" LOG_CI_END="0.09233596524586214" LOG_CI_START="-0.09924479590364918" LOG_EFFECT_SIZE="-0.0034544153288935337" ORDER="25976" O_E="0.0" SE="0.11253548743928524" STUDY_ID="STD-Hashi-1988" TOTAL_1="71" TOTAL_2="69" VAR="0.012664235933197524" WEIGHT="95.3020134228188"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>After one to six months</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.2045099580700085" CI_START="0.03467335491696534" DF="0.0" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-003.02.03" LOG_CI_END="0.5057616254997814" LOG_CI_START="-1.4600041349391062" LOG_EFFECT_SIZE="-0.4771212547196625" NO="3" P_CHI2="1.0" P_Z="0.34138810212716" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="10" WEIGHT="4.697986577181209" Z="0.951426150896346">
<NAME>At six months</NAME>
<DICH_DATA CI_END="3.204509958070007" CI_START="0.03467335491696534" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.5057616254997813" LOG_CI_START="-1.4600041349391062" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="25977" O_E="0.0" SE="1.1547005383792515" STUDY_ID="STD-Mori-1999" TOTAL_1="15" TOTAL_2="10" VAR="1.3333333333333333" WEIGHT="4.697986577181209"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4067836631108752" CI_START="0.3470771132185636" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6987577639751553" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.14822731624001784" LOG_CI_START="-0.4595740234089546" LOG_EFFECT_SIZE="-0.1556733535844684" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.3153819675927445" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="46" TOTAL_2="45" WEIGHT="100.0" Z="1.0039930696906394">
<NAME>Delayed cerebral ischaemia during the scheduled treatment or follow-up period</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4067836631108754" CI_START="0.34707711321856355" EFFECT_SIZE="0.6987577639751553" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.14822731624001792" LOG_CI_START="-0.4595740234089547" LOG_EFFECT_SIZE="-0.1556733535844684" ORDER="25978" O_E="0.0" SE="0.35702551557496087" STUDY_ID="STD-Hasan-1989" TOTAL_1="46" TOTAL_2="45" VAR="0.1274672187715666" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="54" EVENTS_2="31" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="370" TOTAL_2="357" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects of the treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Hypokalemia</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="29" EVENTS_2="16" I2="0.0" ID="CMP-003.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="81" TOTAL_2="78" WEIGHT="0.0" Z="0.0">
<NAME>Hyperglycemia</NAME>
<DICH_DATA CI_END="2.9511943306541966" CI_START="1.0322321705909219" EFFECT_SIZE="1.7453703703703705" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="16" LOG_CI_END="0.46999780792491286" LOG_CI_START="0.013777390184811096" LOG_EFFECT_SIZE="0.24188759905486196" ORDER="25979" O_E="0.0" SE="0.26798613170802543" STUDY_ID="STD-Hashi-1988" TOTAL_1="81" TOTAL_2="78" VAR="0.07181656678783116" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.04.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Any infection</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.04.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Exacerbation of diabetes mellitus</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="4" I2="0.0" ID="CMP-003.04.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="81" TOTAL_2="78" WEIGHT="0.0" Z="0.0">
<NAME>Blood pressure changes</NAME>
<DICH_DATA CI_END="4.318437157070631" CI_START="0.3355155010042713" EFFECT_SIZE="1.2037037037037037" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6353266040226754" LOG_CI_START="-0.47428741038290123" LOG_EFFECT_SIZE="0.08051959681988707" ORDER="25980" O_E="0.0" SE="0.6517927647397918" STUDY_ID="STD-Hashi-1988" TOTAL_1="81" TOTAL_2="78" VAR="0.4248338081671415" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="6" I2="0.0" ID="CMP-003.04.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="81" TOTAL_2="78" WEIGHT="0.0" Z="0.0">
<NAME>Gastrointestinal bleeding</NAME>
<DICH_DATA CI_END="3.194929185840521" CI_START="0.395049494326258" EFFECT_SIZE="1.123456790123457" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.5044612366604514" LOG_CI_START="-0.40334848977556365" LOG_EFFECT_SIZE="0.05055637344244389" ORDER="25981" O_E="0.0" SE="0.533251927039135" STUDY_ID="STD-Hashi-1988" TOTAL_1="81" TOTAL_2="78" VAR="0.284357617690951" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="1.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="13" EVENTS_2="5" I2="0.0" ID="CMP-003.04.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="127" TOTAL_2="123" WEIGHT="0.0" Z="0.0">
<NAME>Other</NAME>
<DICH_DATA CI_END="6.648688139857462" CI_START="0.14393731647383476" EFFECT_SIZE="0.9782608695652174" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8227359626227094" LOG_CI_START="-0.8418265984351703" LOG_EFFECT_SIZE="-0.009545317906230389" ORDER="25982" O_E="0.0" SE="0.9777722880829642" STUDY_ID="STD-Hasan-1989" TOTAL_1="46" TOTAL_2="45" VAR="0.9560386473429952" WEIGHT="0.0"/>
<DICH_DATA CI_END="12.178846178750268" CI_START="1.0236603532408335" EFFECT_SIZE="3.5308641975308643" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" LOG_CI_END="1.0856061452805938" LOG_CI_START="0.01015588322019266" LOG_EFFECT_SIZE="0.5478810142503933" ORDER="25983" O_E="0.0" SE="0.6317248074989343" STUDY_ID="STD-Hashi-1988" TOTAL_1="81" TOTAL_2="78" VAR="0.3990762324095657" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" NO="4">
<NAME>Glucocorticoid treatment versus control in PICH</NAME>
<DICH_OUTCOME CHI2="3.556809699252997" CI_END="1.3543424315090342" CI_START="0.8745775404631617" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0883370216500352" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="55" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.13172848511171864" LOG_CI_START="-0.058201679721733596" LOG_EFFECT_SIZE="0.03676340269499252" METHOD="MH" NO="1" P_CHI2="0.46929309766335514" P_Q="0.0" P_Z="0.4480009364936888" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="102" TOTAL_2="104" WEIGHT="100.00000000000001" Z="0.7587519896538008">
<NAME>Death at the end of follow up</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.8851619420089816" CI_END="1.4176565661495746" CI_START="0.9121128548809705" DF="3.0" EFFECT_SIZE="1.1371291825432333" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="50" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="0.15157103374479755" LOG_CI_START="-0.03995142349196109" LOG_EFFECT_SIZE="0.05580980512641824" NO="1" P_CHI2="0.4096720577701315" P_Z="0.2533416986896748" STUDIES="4" TAU2="0.0" TOTAL_1="92" TOTAL_2="94" WEIGHT="90.9161217675469" Z="1.1422703072022249">
<NAME>At one month</NAME>
<DICH_DATA CI_END="12.399839261423173" CI_START="0.6860527999673501" EFFECT_SIZE="2.9166666666666665" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.093416055458251" LOG_CI_START="-0.16364245885294934" LOG_EFFECT_SIZE="0.4648867983026508" ORDER="25984" O_E="0.0" SE="0.7384023938464008" STUDY_ID="STD-Desai-1998" TOTAL_1="12" TOTAL_2="14" VAR="0.5452380952380952" WEIGHT="3.354047347367304"/>
<DICH_DATA CI_END="1.2658218111247144" CI_START="0.8189890597278491" EFFECT_SIZE="1.018181818181818" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" LOG_CI_END="0.1023725746451308" LOG_CI_START="-0.08672189962121778" LOG_EFFECT_SIZE="0.007825337511956526" ORDER="25985" O_E="0.0" SE="0.11107503021679689" STUDY_ID="STD-Ogun-2001" TOTAL_1="15" TOTAL_2="12" VAR="0.012337662337662342" WEIGHT="22.205035679329832"/>
<DICH_DATA CI_END="1.5990366782229426" CI_START="0.6528623544907048" EFFECT_SIZE="1.0217391304347827" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="21" LOG_CI_END="0.20385842557684103" LOG_CI_START="-0.1851783730685542" LOG_EFFECT_SIZE="0.009340026254143432" ORDER="25986" O_E="0.0" SE="0.22852214128751674" STUDY_ID="STD-Poungvarin-1987" TOTAL_1="46" TOTAL_2="47" VAR="0.05222236905863177" WEIGHT="37.742048914192296"/>
<DICH_DATA CI_END="1.5608435700600831" CI_START="0.8835474653881039" EFFECT_SIZE="1.174342105263158" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.1933593796390027" LOG_CI_START="-0.053770114632123805" LOG_EFFECT_SIZE="0.06979463250343948" ORDER="25987" O_E="0.0" SE="0.14516508824558566" STUDY_ID="STD-Tellez-1973" TOTAL_1="19" TOTAL_2="21" VAR="0.02107290284534867" WEIGHT="27.614989826657467"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8603415693671976" CI_START="0.19351285050435946" DF="0.0" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-004.01.02" LOG_CI_END="0.2695926904933655" LOG_CI_START="-0.7132901897260783" LOG_EFFECT_SIZE="-0.22184874961635637" NO="2" P_CHI2="1.0" P_Z="0.376277501209928" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="9.083878232453115" Z="0.8847759341707597">
<NAME>At six months</NAME>
<DICH_DATA CI_END="1.860341569367198" CI_START="0.1935128505043594" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.2695926904933656" LOG_CI_START="-0.7132901897260784" LOG_EFFECT_SIZE="-0.22184874961635637" ORDER="25988" O_E="0.0" SE="0.5773502691896258" STUDY_ID="STD-Hooshmand-1972" TOTAL_1="10" TOTAL_2="10" VAR="0.33333333333333337" WEIGHT="9.083878232453115"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5194763294980357" CI_END="1.085003757434288" CI_START="0.8303184201980912" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9491567867227368" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="64" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.03543124217547161" LOG_CI_START="-0.080755327364416" LOG_EFFECT_SIZE="-0.02266204259447218" METHOD="MH" NO="2" P_CHI2="0.7712535133345227" P_Q="0.0" P_Z="0.4445234970484855" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="73" TOTAL_2="73" WEIGHT="100.00000000000001" Z="0.7645769640531395">
<NAME>Poor outcome at the end of follow up</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5194763294980357" CI_END="1.085003757434288" CI_START="0.8303184201980912" DF="2.0" EFFECT_SIZE="0.9491567867227368" ESTIMABLE="YES" EVENTS_1="61" EVENTS_2="64" I2="0.0" ID="CMP-004.02.01" LOG_CI_END="0.03543124217547161" LOG_CI_START="-0.080755327364416" LOG_EFFECT_SIZE="-0.02266204259447218" NO="1" P_CHI2="0.7712535133345227" P_Z="0.4445234970484855" STUDIES="3" TAU2="0.0" TOTAL_1="73" TOTAL_2="73" WEIGHT="100.00000000000001" Z="0.7645769640531395">
<NAME>At one month</NAME>
<DICH_DATA CI_END="1.3540816874872081" CI_START="0.69804950330343" EFFECT_SIZE="0.9722222222222222" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.1316448647588914" LOG_CI_START="-0.15611377759291467" LOG_EFFECT_SIZE="-0.012234456417011635" ORDER="25989" O_E="0.0" SE="0.1690308509457034" STUDY_ID="STD-Desai-1998" TOTAL_1="12" TOTAL_2="14" VAR="0.028571428571428595" WEIGHT="17.346101703696668"/>
<DICH_DATA CI_END="1.2658218111247144" CI_START="0.8189890597278491" EFFECT_SIZE="1.018181818181818" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" LOG_CI_END="0.1023725746451308" LOG_CI_START="-0.08672189962121778" LOG_EFFECT_SIZE="0.007825337511956526" ORDER="25990" O_E="0.0" SE="0.11107503021679689" STUDY_ID="STD-Ogun-2001" TOTAL_1="15" TOTAL_2="12" VAR="0.012337662337662342" WEIGHT="19.139602960097402"/>
<DICH_DATA CI_END="1.1035168696275157" CI_START="0.7704364306419793" EFFECT_SIZE="0.9220572640509014" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="41" LOG_CI_END="0.04277897667315348" LOG_CI_START="-0.11326318947034772" LOG_EFFECT_SIZE="-0.03524210639859711" ORDER="25991" O_E="0.0" SE="0.09165994081387242" STUDY_ID="STD-Poungvarin-1987" TOTAL_1="46" TOTAL_2="47" VAR="0.008401544750002595" WEIGHT="63.51429533620593"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>At six months</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="27" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="208" TOTAL_2="216" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects of the treatment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Hypokalemia</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-004.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Hyperglycemia</NAME>
<DICH_DATA CI_END="16.719183354613097" CI_START="0.08141014320149548" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2232150605882353" LOG_CI_START="-1.0893214813270087" LOG_EFFECT_SIZE="0.06694678963061322" ORDER="25992" O_E="0.0" SE="1.3583954119615156" STUDY_ID="STD-Desai-1998" TOTAL_1="12" TOTAL_2="14" VAR="1.8452380952380953" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="2.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="17" EVENTS_2="14" I2="0.0" ID="CMP-004.03.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="3" TAU2="0.0" TOTAL_1="73" TOTAL_2="73" WEIGHT="0.0" Z="0.0">
<NAME>Any infection</NAME>
<DICH_DATA CI_END="1.5189935102793355" CI_START="0.16458266497401045" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.18155591839478474" LOG_CI_START="-0.7836159097227472" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="25993" O_E="0.0" SE="0.5669467095138409" STUDY_ID="STD-Desai-1998" TOTAL_1="12" TOTAL_2="14" VAR="0.3214285714285714" WEIGHT="0.0"/>
<DICH_DATA CI_END="11.504010136151432" CI_START="0.05563277434785942" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0608492556946398" LOG_CI_START="-1.2546692817107525" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="25994" O_E="0.0" SE="1.3601470508735443" STUDY_ID="STD-Ogun-2001" TOTAL_1="15" TOTAL_2="12" VAR="1.85" WEIGHT="0.0"/>
<DICH_DATA CI_END="5.3253347889716" CI_START="0.9202743987684443" EFFECT_SIZE="2.213768115942029" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="6" LOG_CI_END="0.7263469158539715" LOG_CI_START="-0.03608265949929859" LOG_EFFECT_SIZE="0.3451321281773365" ORDER="25995" O_E="0.0" SE="0.4478549066497766" STUDY_ID="STD-Poungvarin-1987" TOTAL_1="46" TOTAL_2="47" VAR="0.2005740174102801" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="0" I2="0.0" ID="CMP-004.03.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="46" TOTAL_2="47" WEIGHT="0.0" Z="0.0">
<NAME>Exacerbation of diabetes mellitus</NAME>
<DICH_DATA CI_END="197.53847184590916" CI_START="0.6388816867296763" EFFECT_SIZE="11.23404255319149" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.295651689751224" LOG_CI_START="-0.19457956055503464" LOG_EFFECT_SIZE="1.0505360645980948" ORDER="25996" O_E="0.0" SE="1.4627741632733904" STUDY_ID="STD-Poungvarin-1987" TOTAL_1="46" TOTAL_2="47" VAR="2.139708252740167" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.03.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Blood pressure changes</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="2.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="4" I2="0.0" ID="CMP-004.03.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="3" TAU2="0.0" TOTAL_1="77" TOTAL_2="82" WEIGHT="0.0" Z="0.0">
<NAME>Gastrointestinal bleeding</NAME>
<DICH_DATA CI_END="4.383265026887294" CI_START="0.012149490743351265" EFFECT_SIZE="0.23076923076923078" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6417977303470873" LOG_CI_START="-1.9154419255214357" LOG_EFFECT_SIZE="-0.6368220975871743" ORDER="25997" O_E="0.0" SE="1.5021352323976214" STUDY_ID="STD-Desai-1998" TOTAL_1="12" TOTAL_2="14" VAR="2.256410256410256" WEIGHT="0.0"/>
<DICH_DATA CI_END="103.5545857938871" CI_START="0.25180098906769366" EFFECT_SIZE="5.1063829787234045" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0151693358792264" LOG_CI_START="-0.5989425683274494" LOG_EFFECT_SIZE="0.7081133837758886" ORDER="25998" O_E="0.0" SE="1.535542272593622" STUDY_ID="STD-Poungvarin-1987" TOTAL_1="46" TOTAL_2="47" VAR="2.3578900709219854" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.09371827394474" CI_START="0.17220963689612723" EFFECT_SIZE="1.105263157894737" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8508739365322062" LOG_CI_START="-0.7639425489700256" LOG_EFFECT_SIZE="0.043465693781090345" ORDER="25999" O_E="0.0" SE="0.9485511970545312" STUDY_ID="STD-Tellez-1973" TOTAL_1="19" TOTAL_2="21" VAR="0.899749373433584" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-004.03.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Other</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-08-05 13:50:52 +0100" MODIFIED_BY="Hazel Fraser">
<APPENDIX ID="APP-01" MODIFIED="2008-08-05 13:50:52 +0100" MODIFIED_BY="Hazel Fraser" NO="1">
<TITLE MODIFIED="2008-08-05 13:36:11 +0100" MODIFIED_BY="Hazel Fraser">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-08-05 13:50:52 +0100" MODIFIED_BY="Hazel Fraser">
<P>The following search strategy was used for MEDLINE and modified for the other databases.</P>
<P>1. exp intracranial hemorrhages/<BR/>2. vasospasm, intracranial/<BR/>3. intracranial aneurysm/<BR/>4. aneurysm/or aneurysm, ruptured/ or hematoma/<BR/>5. exp brain/ or exp meninges/<BR/>6. 4 and 5<BR/>7. ((brain or intracranial or cerebral or basal ganglia or subarachnoid or intracerebral or putaminal) adj5 (haemorrhage$ or hemorrhage$)).tw.<BR/>8. ((brain or cerebral or intracerebral or intracranial or basilar or communicating artery) adj5 aneurysm$).tw.<BR/>9. ((brain or intracerebral or intracranial or subarachnoid) adj5 (haematoma$ or hematoma$).tw.<BR/>10. (SAH or PICH).tw.<BR/>11. 1 or 2 or 3 or 6 or 7 or 8 or 9 or 10<BR/>12. exp adrenal cortex hormones/<BR/>13. exp glucocorticoids, synthetic/<BR/>14. exp mineralocorticoids, synthetic/<BR/>15. (corticosteroid$ or corticoid$ or glucocorticoid$).tw.<BR/>16. (betamethasone or dexamethasone or methylprednisolone or prednisolone or triamcinolone or fludrocortisone).tw.<BR/>17. (corticosterone or hydrocortisone or hydrocorticosteroids or tetrahydrocort$ or desoxycorticosterone).tw.<BR/>18. 12 or 13 or 14 or 15 or 16 or 17<BR/>19. 11 and 18<BR/>20. limit 19 to human</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>